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ABSTRACT
Chemotherapy is a widely used treatment for cancer, with significant side effects
including cognitive impairments that affect patients’ quality of life. Red raspberries are
known to inhibit growth of cancer cells with recent research suggesting the ability to also
protect neurons. If this protective ability can be confirmed, red raspberry may emerge as
a promising natural intervention for cognitive impairments associated with
chemotherapy. In addition, many studies have linked cognitive functions to epigenetic
mechanisms postulating that transient reprogramming of epigenetic mechanisms, such as
DNA methylation, is required for some basic neuronal/cognitive functions.
The objective of this dissertation is to study the effects of in vitro digested and in
vivo human metabolized red raspberry on doxorubicin chemotherapy initiated
neurotoxicity in nerve growth factor induced PC12 pheochromocytoma neuronal cells,
and explore the underlying epigenetic DNA methylation changes associated with this
process.
Primary results are summarized as: 1) minute amounts, as low as 0.001µM of
doxorubicin reduced the metabolic activity of nerve growth factor induced PC12
neuronal cells, exibiting neurotoxicity; 2) in vitro digested red raspberry counteracted the
toxic effects of doxorubicin chemotherapy on the metabolic activity and neurite growth
of nerve growth factor induced PC12 neuronal cells; 3) participants’ plasma after red
raspberry consumption showed positive effects on metabolic activity of nerve growth
factor induced PC12 neuronal cells treated with doxorubicin chemotherapy; 4) DNA
methylation pattern of FOS gene for nerve growth factor induced PC12 neuronal cells
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treated with doxorubicin was different from the control and in vitro digested red
raspberry treated cells. Possible explanations for these results are discussed.
This dissertation research contributes to a better understanding of neurotoxicity due
to doxorubicin chemotherapy and the neuroprotection of in vitro digested and in vivo
human metabolized red raspberry at the cellular and epigenetic level. This work provides
evidence for future preliminary clinical trials investigating natural red raspberry
consumption as an intervention for cognitive impairments in cancer patients receiving
doxorubicin chemotherapy.
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CHAPTER ONE INTRODUCTION
1.1

Motivation and Objectives
Studies show that chemotherapy may initiate or potentiate cognitive decline

(“chemobrain”) experienced by patients with a variety of types of cancer (Ahles, Aaykin,
& Furstenberg, 2002; Brezden, Phillips, Abdolell, Bunston, & Tannock, 2000; Downie,
Mar Fan, Houede-Tchen, Yi, & Tannock, 2006; Jansen, Cooper, Dodd, & Miaskowski,
2010; Schagen, van Dam, Muller, Boogerd, Lindeboom, & Bruning, 1999; Shilling,
Jenkins, Morries, Deutsch, & Bloomfield, 2005; Wefel, Lenzi, Theriault, Buzdar,
Cruickshank, & Meyers, 2004). Types of decline may include decline in attention,
executive function, processing speed, motor function, learning and memory (Ahles &
Saykin, 2007). The incidence of chemotherapy induced cognitive decline in cancer
patients is reported to be from16% to 75% depending on different study population,
chemotherapy regimens and study methodology (Calvio, Peugeot, Bruns, Todd, &
Feuerstein, 2010). The cognitive changes may persist following completion of treatment
and can significantly impact both the short-term and long-term quality of life for cancer
survivors (Ahles & Saykin, 2007; Ahles et al., 2002). Younger survivors face the
challenge of maintaining competitiveness in their school and jobs, while older survivors
may have increased susceptibility to memory loss resulting in an impaired ability to selfmanage (Nelson, Nandy, & Roth, 2007). Pharmacologic treatments for chemotherapy
induced cognitive decline have been explored. One of these is methylphenidate.
However, there are serious side effects associated with this drug including loss of
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appetite, headache, hair loss, depression, seizures and anemia (Thompson et al., 2001). A
natural intervention with fewer side effects would be well received.
The published evidence from our lab and other research groups indicates that berries
could sensitize tumor cells to chemotherapeutic agents in vitro and in vivo (Aziz et al.,
2002; Chen, Hwang, Rose, Nines, & Stone, 2006a; Duthie, 2007; Kresty et al., 2006;
Tate, Kuzmar, Smith, Wedge, & Larcom, 2003; Lu et al., 2006; Seeram et al., 2006; Tate,
Kuzmar, Smith, & Wedge, 2001; Xue et al., 2001). Some studies have linked multiple
varieties of berries to neuro-protection in vitro and in animal models (Barros, Amaral, &
Ramirez, 2006; Bastianetto, Dumont, Han, & Quirion, 2009; Fortalezas et al., 2010;
Joseph, Shukitt-Hale, & Willis, 2009; Kang, Hur, Kim, Ryu, & Kim, 2006). The known
constituents in berries that exhibit neuro-protective effects are phenolic molecules such as
anthocyanins, flavonols, flavanols, proan-thocyanidins, ellagitannins, and phenolic acids
(Barros et al., 2006; Bastianetto et al., 2009; Fortalezas et al., 2010; Joseph et al., 2009;
Kang et al., 2006; Seeram, 2008). Different types of berries have different combinations
of the noted constituents that exhibit various neuro-protective properties. Although the
extracts of berries (mostly antioxidants) perform well in some aspects, the natural
combination of all the constituents may have the most beneficial effects and least side
effects (Anttonen & Karjalainen, 2005; Aruoma, Bahorun, & Jen, 2003; de Ancos,
Gonzales, & Cano, 2000; Joseph et al., 2009).
In addition, many studies have linked cognitive function to epigenetic mechanisms
postulating that transient reprogramming of epigenetic codes, such as DNA methylation
and histone modifications, is required for some basic cognitive functions such as memory
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consolidation (Feng et al., 2010; Levenson et al., 2006; Miller & Sweatt, 2007; Lubin et
al., 2008; Korzus, Rosenfeld, & Mayford, 2004; Miller, Campbell & Sweatt, 2008). As
shown in Figure 1.1, folate, another important natural constituent in berries, is an
indispensable element in the pathway of epigenetic methylation, contributing to the
provision of methyl groups to S-adenosylmethionine (SAM) for use in methylation (Lu,
Wylie, Andrews, & Tollefshol, 2003). Therefore, the intake of folate influences the
availability of methyl groups for DNA or histone methylation. When methylated, DNA
or histones will recruit different chromatin remodeling complexes to promote the
compacting or opening of chromatin in order to regulate gene transcription. The
activation and silencing of genes, such as EGR1, FOS and BDNF, important in neuronal
functions, can lead to changes in cognitive functions (Aid, Kazantseva, Piirsoo, &
Timmusk, 2007; Bozon, Davis, & Laroche, 2002; Hu et al., 1994).
In summary, many cancer patients experience cognitive decline after treatment with
certain types of chemotherapy (Schagen et al., 1999; Brezden et al., 2000; Ahles et al.,
2002; Wefel et al., 2004; Shilling et al., 2005; Downie et al., 2006; Jansen et al., 2010).
Epigenetic modifications have been shown to be a key factor in cognitive functions
especially memory formation (Feng et al., 2010; Levenson et al., 2006; Miller & Sweatt,
2007; Lubin et al., 2008; Korzus et al., 2004; Miller et al., 2008). Berries have been
shown to involve in epigenetic modifications (Lu et al., 2003), protect neurons (Joseph et
al., 2009; Barros et al., 2006; Bastianetto et al., 2009; Fortalezas et al., 2010; Kang et al.,
2006; Seeram, 2008), and inhibit cancer progression (Seeram et al., 2006; Tate et al.,
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2003; Wedge et al., 2001; Xue et al., 2001; Kresty et al., 2006; Aziz et al., 2002; Duthie
2007; Chen et al., 2006a; Lu et al., 2006).
Based on the above reviewed research, the over-reaching research question focuses
on whether red raspberry (RR) can prevent cognitive decline experienced by cancer
patients receiving chemotherapy. To provide the basic scientific foundation necessary to
answer this question, the objective of this dissertation is to study the effects of in vitro
digested RR and in vivo human metabolized RR on doxorubicin (DOX) chemotherapy
initiated neurotoxicity, and explore the underlying epigenetic DNA methylation changes
associated with this process. The model system was nerve growth factor (NGF) induced
pheochromocytoma (PC12) neuronal cells (NGF induced PC12 neuronal cells will be
designated as ‘PC12 neuronal cells’). In order to achieve the objective, the following
specific aims are addressed:
Identify the effects of DOX chemotherapy on the metabolic activity of PC12
neuronal cells;
Identify the effects of in vitro digested RR on the metabolic activity of PC12
neuronal cells;
Describe the effects of in vitro digested RR on the metabolic activity of DOX
chemotherapy treated PC12 neuronal cells;
Describe the effects of in vitro digested RR on the neurite growth of DOX
chemotherapy treated PC12 neuronal cells;
Compare the effects of human plasma collected from healthy donors prior to and
after RR consumption on DOX treated PC12 neuronal cells; and
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Identify the effects of DOX, in vitro digested RR and their combination treatments
on the DNA methylation of PC12 neuronal cells.

1.2

Literature Review

1.2.1 Chemotherapy Induced Cognitive Decline and Neurotoxicity
Many cancer patients experience cognitive decline associated with chemotherapy
treatments. For some of these patients, cognitive function declines subtly and often
improves after ceasing chemotherapy; however, for a subset of cancer survivors, the
symptoms persist and significantly impact their ability to function and their quality of life
(Vardy, Wefel, Ahles, & Tannock, & Schagen, 2008).
A number of studies have looked at the cognitive decline in cancer patients
receiving chemotherapy (Ahles et al., 2002; Brezden et al., 2000; Downie et al., 2006;
Jansen et al., 2010; Schagen, Muller, Boogerd, Mellenbergh, & van Dam, 2006; Schagen
et al., 1999; Shilling et al., 2005; Tannock, Ahles, Ganz, & van Dam, 2004; Vardy et al.,
2006; Wefel et al., 2004; Vardy & Tannock, 2007). However, the methodological
limitations and variations of these studies restricted the validity and generalization of
results. Specifically, selection of controls, selection of cognitive batteries,
identification/measurement of confounding variables, and measurement intervals are
some of the key factors that differed in the research designs.
Studies were performed using different control groups (Schagen et al., 2006;
Shilling et al., 2005). The best controls were those that closely resembled the treatment
groups, but only differed in independent variables and some to-be-measured confounding
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variables. For example, to look at cognitive decline associated with chemotherapy, the
control group should be cancer patients who are not undergoing chemotherapy. Healthy
controls should also be included if possible.
The longitudinal study by Schagen et al. (2006) compared the cognitive changes for
four groups of patients: those with high dose chemotherapy with cyclophosphamide,
thiotepa, and carboplatin (N = 39), standard dose chemotherapy with 5-fluorouracil,
epirubicin, and cyclophosphamide (N = 28), no chemotherapy (N = 57) and healthy
volunteers (N = 60). The neuropsychological examination consisted of 10 tests and 24
indices covering tests such as working-verbal-visual memory, attention, and executive
function. The researchers identified that patients receiving high dose chemotherapy had
significantly more cognitive decline than healthy controls (p < 0.02) while the other
groups showed a non-significant decline trend compared with healthy controls (p = 0.2).
Though this study did not show statistically significant results of cognitive decline for
those receiving standard chemotherapy doses, the clinical relevance indicated in a
downward trend should not be ignored.
A study by Shilling et al. (2005) evaluated three groups of patients: those to receive
different chemotherapy regimens (N = 85), those to receive hormone treatment (N = 43),
and a group of healthy controls (N = 49). Pre-tests, 6-month post-tests and 12-month
post-tests results were obtained. There were no significant differences in overall
cognitive function including visual-working memory, intelligence, and processing speed
among groups. Nevertheless, a clinically relevant trend of cognitive decline was
observed in all groups. Interestingly, the hormone group showed the largest decline of
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26%, while the chemotherapy group was next with 20%. As anticipated, the healthy
control group showed the least decline of 18%.
Studies were performed using different cognitive batteries. The most discrepancies
of cognitive batteries were found between subjective self-report assessments and
objective neuropsychological assessments. To emphasize this problem, Downie et al.
(2006) compared the assessments using self-report questionnaires and a researcheradministered screen of cognitive functions. Of participants whose memory was measured
by the researcher-administered neuropsychological assessment, 48% had difficulties with
memory. Ninety-five percent of participants who self-reported their experiences noted
memory problems. Two other studies (Schagen et al., 1999; Vardy et al., 2006) indicated
the self-reported incidence was more associated with affective change (emotional change,
anxiety and depression) than objective impairment. However, it was noted that selfreporting can capture some aspects that objective tests miss, such as ability to multitask
or daily work under relevant conditions (Tannock et al., 2004). Evaluating cognitive
decline is difficult because of the following reasons. First, there are numerous cognitive
batteries that can be used for measurement. Both individual domain score, evaluating
one of the cognitive function domains such as processing speed, attention, memory
retrieval, executive function, and multiple domain scores can be used in a study. In
addition, there are different ways to administer the cognitive tests. For example, tests can
be researcher-directed or self-directed, paper-based or computer-based. But the
differences in communication of instructions, stimulus presentation, and response format
may yield significant differences in test performance (Wild, Howieson, Webbe, Seelye,
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& Kaye, 2008). There are also numerous ways to define abnormal performance of
cognitive functions since different cut-off points for detecting impairments can be applied
(Vardy et al., 2008). Succinctly, there is not a standardized assessment guideline and
methodology that can be used.
Studies were performed measuring different confounding variables. Brezden et al.
(2000) investigated differences in cognitive function between breast cancer patients
treated with standard-dose adjuvant chemotherapy (either cyclophosphamide, epirubicin,
and fluorouracil, or cyclophosphamide, methotrexate, and fluorouracil) versus healthy
controls. The High Sensitivity Cognitive Screen and the Profile of Mood States (POMS)
tools were used to assess memory, language, visual-motor, spatial, attention,
concentration, self-regulation, planning and mood of the participants. Memory domains
were observed to be different between the treatment group and healthy controls (p =
0.024), suggesting impairment in memory domains for patients receiving chemotherapy.
However, besides mood change, other possible confounding variables such as preexisting cognitive differences, fatigue, anxiety, depression, stress, hormone levels, and
other mediators were not considered. Ahles and colleagues (2002) compared the
neuropsychological functions of long-term survivors of breast cancer and lymphoma who
were 5 years post-diagnosis, not presently receiving cancer treatments, and disease-free.
Scores of participants who had been treated with standard-dose systemic chemotherapy
regimens (N = 35) were compared with those of participants who had been treated with
local therapy only (N = 35). Controlling for age, education and some psychological
factors including depression, anxiety and fatigue (by Center for Epidemiological Study-
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Depression, Spielberger State-Trait Anxiety Inventory, and Fatigue Symptom Inventory),
the study revealed that survivors who had undergone systemic chemotherapy scored
significantly lower on the battery of neuropsychological tests (p < 0.04), particularly in
the domains of verbal memory (p < 0.01) and self-report working memory (p < 0.02). A
lack of pre-test of cognitive functions was identified as a study limitation, since there was
a possibility that some patients may have scored above normal and other patients may
have scored below normal before treatment, thus skewing the outcome of the research.
Many other studies on cognitive decline in cancer patients who have received
chemotherapy were completed without a pre-test. One study illustrated the need for
inclusion of pre-tests. Wefel et al. (2004) used comprehensive neuropsychological
evaluation to assess women with breast cancer (N = 84) prior to receiving adjuvant
therapy for non-metastatic primary breast carcinoma. The researchers found that prior to
chemotherapy, 25% of the patients had impaired memory, a significant finding when
compared to normative expectations. These results emphasize the importance to employ
study designs that incorporate pre-chemotherapy baseline assessments in order to
accurately measure chemotherapy-induced cognitive decline. In addition, the timing of
pre-tests is also important. The only realistic time is after diagnosis and before any
treatment such as surgery or hormonal medication. However, the stress related to a new
life-threatening diagnosis or life- altering surgery can be a possible confounding variable,
and should be considered (Vardy & Tannock, 2007).
As shown in Figure 1.2, the mechanisms that cause the disruption of cognitive
function by chemotherapy remain unknown. However, there are contributing factors that
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are associated with this process, such as direct neurotoxic effects, genetic susceptibility,
oxidative stress, DNA damage, cytokine and hormone changes.
First, chemotherapy is a known factor that can directly cause neuronal cell death or
reduced proliferation of brain neurons. Dietrich et al. (2006) administered the three
mainstream chemotherapeutic agents carmustine (BCNU), cisplatin, and cytosine
arabinoside (cytarabine) in vitro to multiple cell lines and in vivo to CBA mice. They
found these agents are associated with increased cell death and decreased cell division in
the subventricular zone, in the dentate gyrus of the hippocampus and in the corpus
callosum of the central nervous system (CNS) in mice.
Although chemotherapeutic agents are generally assumed to be unable to cross the
blood-brain barrier, more and more chemotherapeutic agents have been reported to cross
the blood-brain barrier in standard doses including methotrexate, cisplatin, cytarabine,
ifosfamide, procarbazine, temozolomide, carmustine, lomustine (Wilkes & Barton-Burke,
2007; Myers, Piercem & Pazdernik, 2008). The mechanisms of how this movement
occurs remain almost unknown except for one plausible explanation: genetic
polymorphisms or mutations in drug transporters in blood-brain barrier. For example, Pglycoprotein, encoded by the multidrug resistance1 (MDR1) gene and expressed in the
capillary endothelial cells in the blood-brain barrier, is responsible for keeping
unwelcomed drugs out of brain. Several polymorphisms of the MDR1 gene have been
identified that may influence the expression and functions of this guard keeper
(Jamroziak et al., 2004; Ahles & Saykin, 2007). Genetic polymorphisms or mutations in
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drug transporters in blood-brain barrier can also explain the phenomenon that not all
patients treated with the same chemotherapy are subject to cognitive decline.
Second, genetic variability or mutations in brain plasticity genes and
neurotransmitter genes may account for the long-term cognitive changes in chemotherapy
treated cancer patients. For example, people with the E4 allele for the gene that encodes
apolipoprotein E (APOE), a glycolipoprotein in charge of neuronal repair and plasticity
after injury, may not be easily recovered from any injury induced by detrimental agents
(Morley & Montgomery, 2001). That is, these patients will need more time to recover or
even cannot recover from the cognitive injury. Detrimental agents may include
chemotherapy that crosses the blood-brain barrier, or any physiological change secondary
to this type of cancer treatment.
Third, chemotherapy has been associated with increased DNA damages, increased
free radicals, and decreased antioxidant activities that can lead to oxidative stress, as
observed in cancer patients who develop anemia as a side effect of chemotherapy (Kaya,
2005; Ahles & Saykin, 2007). There is some literature that relates oxidative stress and
DNA damage to Alzheimer’s disease (AD), aging, and other types of cognitive
impairments (Butterfield & Kanski, 2001; Butterfield & Lauderback, 2002; Butterfield,
Perluigi & Sultana, 2006; Mariani, Polidori, Cherubini, & Mecocci, 2005; Poon,
Calabrese, Calvani, & Butterfield, 2006). Unlike genetic polymorphisms, oxidative
stress and DNA damage are secondary physiological changes, due to physiological
mechanisms of cancer, chemotherapy and / or the combination of both, which can affect
cognition in patients with cancer.
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It has been reported that more pro-inflammatory cytokines are released in women
with breast cancer than in women with a negative breast biopsy (Lyon, McCain, &
Walter, 2008). Pro-inflammatory cytokines are associated with cognitive decline and
sickness behaviors. These primarily include fatigue, decreased social interaction,
decreased concentration, decreased executive function, stress and depression. The
proposed mechanisms for cytokines to cross the blood-brain barrier and affect cognitive
functions include active transport, penetration in areas with fenestrated junctions, binding
to receptors inside the blood vessels to activate secondary messengers that enter brain,
and activation of vagus nerve (Maier & Watkins, 1998; Myers et al., 2008; Maier &
Watkins, 2003).
There are other chemical messengers with the ability to pass through the blood-brain
barrier such as steroid and thyroid hormones. They pass through the blood-brain barrier
by carrier-mediated transport or plasma protein-mediated transport (Pardridge, 1988).
Reductions of chemical messengers like estrogen and testosterone have been reported to
associate with cognitive decline in cancer patients (Galea, Kavaliers, & Ossenkopp, 1995;
Salminen, Portin, Koskinen, Helenius, & Nurmi, 2004).
Interestingly, most of the studies on chemo-brain were done on breast cancer
patients. One possibility is that women with breast cancer experience more hormone
fluctuations, thus have higher susceptibility of cognitive changes. First, many of the
established risk factors of breast cancer are linked to estrogens, such as menarche,
menopause, endogenous/exogenous estradiol, childbearing and breastfeeding (Key,
Verkasalo, & Banks, 2001). Second, chemotherapy can induce an early and abrupt
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menopause that can also cause cognitive decline. Once again, most breast cancer patients
are women that are subject to this chemically induced menopause. Third, tamoxifen and
aromatase inhibitors, often administered for women with breast cancer, compete for
estrogen receptors and cause reduced levels of estrogen hormones. Finally, it has been
reported that some cytokines are involved in regulation of estrogen in breast cancer
patients with the release of cytokines leading to stimulation of estrogen synthesis
(Purohit, Newman, & Reed, 2002). Considering all of the above estrogenic factors, it is
probable that women with breast cancer undergoing menopause during the treatment, or
with an estrogen receptor positive (ER+) tumor therefore administered hormone receptor
inhibitors, or confirmed to have physiological hormonal decline may have a higher risk of
cognitive decline during chemotherapy treatment.
Doxorubicin chemotherapy, specifically included in this dissertation study, was
isolated from cultures of a mutant Streptomyces peucetius (Streptomyces peucetius
caesius) in the Farmitalia Research Laboratories in 1967 (Arcamone, Cassinelli,
DiMarco, & Gaetani 1967; Bonadonna, Monfardini, Lena, & Fossati-Bellani, 1969).
Historically, DOX is one of the most widely used systematic treatments for all types of
cancers including adult breast cancer, soft tissue sarcomas, aggressive lymphomas, and
childhood solid tumours (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004).
Although DOX was not originally believed to cross the blood-brain barrier (Ohnishi et
al., 1995), it is well documented that this chemotherapy can induce neurotoxicity in vitro
and cognitive dysfunction in vivo (Freeman and Broshek, 2002; Konat, Kraszpulski,
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James, Zhang, & Abraham, 2008; Lopes, Meisel, Dirnagl, Carvalho, & Bastos, 2008;
Joshi et al., 2005; Meyers, 2000; Schagen et al., 2006; Tangpong et al., 2006).
Recently, studies have linked epigenetic mechanisms to cognitive function. It is
postulated that transient reprogramming of epigenetic codes such as DNA methylation
and histone modifications is required for some basic cognitive functions, especially
memory formation. The next section will review the literature which illustrates the
possible epigenetic control of memory functions, thus emphasizing the possibility of the
involvement of epigenetic modifications in chemotherapy induced cognitive decline and
neurotoxicity.

1.2.2 Epigenetics and Cognition
Epigenetics was originally defined as “the study of how genotypes give rise to
phenotypes through programmed changes during development (Waddington, 1942, p. 1819)” to describe the cell-to-cell phenotypic alterations during the development in a
multicellular organism. With the knowledge that all the cells in an organism share
identical DNA sequences, but may remarkably differ in their phenotypic expressions,
epigenetics was later defined as “nuclear inheritance that is not based on differences in
DNA sequence (Holliday, 1994, p. 453)”. Subsequently, several other definitions were
developed, but without substantive changes or wide recognition (Allis, Jenuwein,
Reinberg, & Caparros, 2006; Russo, Martienssen, & Riggs, 1996; Wu & Morries, 2001).
In 2009, Berger and colleagues defined epigenetics as “the study of heritable changes in
gene expression that do not involve coding sequence modifications” (Berger, Kouzarides,
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Shiekhattar, & Shilatifard, 2009, p. 781). This definition is comprehensive in that it
includes other modifications besides chromatin patterning in the nucleus, such as RNA
interference, leading scientists to a world of epigenetic possibilities (Volpe et al., 2002;
Tchuikov et al., 2004; Lippman et al., 2004). However, since epigenetic marks can be
transient and are not necessarily heritable, especially for the post-mitotic neurons targeted
in this dissertation, a less comprehensive and more appropriate definition of epigenetics
will be used. This definition states epigenetics is: “ the structural adaptation of
chromosomal regions so as to register, signal or perpetuate altered activity states” (Bird,
2007, p. 398).
The evidence-based epigenetic mechanisms primarily include DNA methylation,
histone acetylation, histone methylation, histone phosphorylation, histone ubiquitylation
and RNA interference, all of which are interrelated. Since little research has been done
regarding the regulation of memory by other epigenetic mechanisms, this section of the
literature review primarily focuses on the regulation of memory formation by DNA
methylation and histone acetylation.
As shown in Figure 1.3, DNA methylation occurs at the cytosine of 5’-cytosine
guanine-3’ (CG) dinucleotides with SAM as the methyl donor and DNA
methyltransferases (Dnmts) as the catalysts (Miranda & Jones, 2007). These methylated
cytosines (methylcytosines) occur on ~ 70-80% of CG dinucleotides throughout the
genome (Attwood, Yung, & Richardson, 2002). When DNA methylation occupies the
spaces where transcriptional factors usually bind, the downstream gene is silenced and no
gene product (protein) is produced.
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Methylated DNA also recruits methylcytosine-binding proteins, and subsequently
other proteins to contribute to the formation of condensed chromatin (heterochromatin as
illustrated in Figure 1.4). Heterochromatin may cause the silence of a neighborhood of
genes, because the transcriptional factors may lose access to a segment of DNA once
chromatin is condensed.
As shown in Figure 1.4, heterochromatin can be relaxed by some of the histone
modifications including the most investigated histone acetylation. Histone acetylation
involves the binding of acetyl groups to lysines in the tails of histones, which is catalyzed
by histone acetyltransferases (HATs) and reversed by histone deacetylases (HDACs)
(Levenson & Sweatt 2005). Histone acetylation usually balances the positive charge on
histone tails, reduces the interaction between positively charged histones and negatively
charged DNA backbone, relaxes the chromatin structure so that the genes are more
accessible to transcriptional factors for transcription (Shahbazian & Grunstein, 2007;
Wade, Pruss, & Wloffe, 1997;Watson et al., 2007). In addition, combinations of histone
acetylation and other histone modifications including histone phosphorylation,
methylation, ubiquitination and ADP-ribosylation, serve as a unique histone language
that is read by other proteins, such as bromo-domain containing proteins, to bring about
downstream events and regulate transcription (Annunziato & Hansen, 2000; Li et al.,
2008; Margueron, Trojer, & Reinberg, 2005; Strahl & Allis, 2000). Recent research
indicates epigenetic mechanisms such as DNA methylation and histone
acetylation/deacetylation may be critical for the changes that underlie cognition
especially learning and long-term memory.
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Levenson and Sweatt et al. (2006) were the first to hypothesize that DNA
methyltransferase activity regulates synaptic plasticity, the ability to change in strength of
synaptic connections, in the central nervous system; therefore suggesting methylation as a
potential epigenetic mechanism associated with long-term memory formation. To test the
hypothesis, the researchers used methylation inhibitors, zebularine and 5-aza-2deoxycytidine, to inhibit DNA methyltransferase activity in hippocampal areas and
evaluated in slices from euthanized mice. After the inhibition, it was noted the promoter
regions of the memory promoting genes Reelin and brain-derived neurotrophic factor
(BDNF) experienced rapid and dramatic decreases in DNA methylation (2006). It is
projected this process contributed to the failure of long-term potentiation (a type of
synaptic plasticity) induction at hippocampal Schaffer collateral synapses that is
implicated to be important in long-term memory consolidation.
After the first in vitro evidence, Miller et al. (2007) implemented an in vivo study to
carefully illustrate that DNA methylation is not only associated with, but crucial and
necessary in long-term memory formation (Miller & Sweatt, 2007). For this experiment,
researchers first induced a group of adult male rats (Sprague Dawley) with a contextual
fear conditioning (CFC) test. After sacrificing, the DNA methylation pattern of several
genes in the hippocampus was analyzed. Rapid methylation (transcriptional silencing) of
the memory suppressor gene PP1, and demethylation (activation) of the memory
promoting gene Reelin were found after CFC, but not prior to. Second, these researchers
randomly assigned another set of adult male Sprague Dawley rats into two groups. In
group one: the experimental rats received the training for the CFC test, then a combined
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injection of DNA methyltransferase inhibitors, zebularine and 5-aza-2-deoxycytidine. In
group two: the control rats also received training for the CFC test, then an injection of
placebo. The performance in subsequent CFC tests was compared for both groups. The
researchers found that after blocking the DNA methyltransferase activity using DNA
methyltransferase inhibitors, the rats “froze” less in the CFC test compared to their
placebo counterparts, indicating a decrease in long-term memory. Using similar
methodology with the CFC and the same type of rats, these researchers found changes in
methylation affected differential regulation of BDNF gene expression, together with
alterations in chromatin structure, again indicating the critical role of DNA methylation
in the formation of long-term memory (Lubin, Roth, & Sweatt, 2008).
In 2010, a study by Feng et al. also illustrated that DNA methylation is required for
long-term memory. These researchers’ engineered DNA methyltransferase 1 and DNA
methyltransferase 3a double conditional knockout (DKO) mice to determine if complete
loss of gene expression of these two proteins in forebrain neurons would lead to abnormal
memory function. Results indicated a number of genes in forebrain neurons of these
DKO mice had an abnormal methylation pattern, deregulated expression, causing deficits
in the ability to learn and memorize. A neuronal loss was not identified, but the neurons
did appear smaller than those seen in the wild type mice (Feng et al., 2010).
The association of DNA methylation and intellectual disability can be illustrated by
fragile X syndrome (FXS). As the most common inherited intellectual disability,
approximately 1 in 4,000 males, FXS can be caused by hypermethylation of CGG repeats
in the 5’ untranslated (UTR) region of the fragile X mental retardation gene (FMR1),
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causing the absence of its product, fragile X mental retardation protein (FMRP) (Garber,
Visootsak, & Warren, 2008; Godler et al., 2010). Another research group reported that
treatment of fragile X cell line by methylation inhibitor 5-aza-2-deoxycytidine can cause
passive demethylation of the FMR1 gene promoter and reactivate the gene expression in
vitro (Pietrobono et al., 2002).
Compared to DNA methylation, there is more evidence indicating the importance of
histone acetylation and deacetylation in learning and memory. Although not the first to
illustrate the effect of histone regulation in neuronal physiological changes, Levenson et
al. were the first to test the regulation of memory and learning by histone acetylation in
vivo. These researchers used HDAC inhibitors, trichostatin A or sodium butyrate, to
elevate the level of histone acetylation and found it enhanced long-term potentiation at
Schaffer-collateral synapses in vitro. Consequently, the injection of histone deacetylase
inhibitors prior to contextual fear conditioning enhanced formation of long-term memory
in vivo (Levenson et al. 2004). However, there is evidence suggesting that nonspecific
HDAC inhibitors, including sodium valproate, sodium butyrate and vorinostat, only
blocked the activity of class I HDACs (Kilgore et al., 2010). The inhibition of class I
HDACs using these nonspecific inhibitors restored contextual memory in an early stage
Alzheimer’s disease APPswe/PS1dE9 double-transgenic mouse model (Kilgore et al.,
2010). This indicates that some HDACs are more crucial in the regulation of long-term
memory than others. Indeed, Guan et al. revealed that forebrain overexpression of
HDAC2, but not HDAC1, negatively regulates memory formation, and McQuown et al.
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illustrated that HDAC3 is also a critical negative regulator of long-term memory (Guan et
al., 2009; McQuown et al., 2011).
Fischer et al. (2007) engineered a bi-transgenic mouse model with learning and
memory deficit by inducing post-natal expression of protein p25. Protein p25 is an
abnormal truncated form of protein p35 which interacts with a protein kinase Cdk5 to
regulate normal development of the mammalian central nervous system (Patrick et al.,
2001). However, the interaction of p25 with Cdk5 can cause neuronal cell death and lead
to learning and memory deficits (Patrick et al., 1999; Lee et al., 2000; Nath et al., 2000).
In addition to inhibitors of histone deacetylases, Fischer et al. found that two other
variables, an enriched environment with a variety of frequently changed toys as well as
exercise (two wheels for voluntary running) have the ability to increase histone
acetylation in brain neurons of mice (Fischer, Sananbenesi, Wang, Dobbin, Tsai, 2007;
Korzus, 2010). Together, these factors have the ability to reverse learning deficit in bitransgenic mice, and re-establish access to long-term memory.
The chromatin remodeling histone acetyltrasnferase activity of CREBBP (cAMPresponsive element binding protein binding protein) has also been linked to formation of
long-term memory and mental deficits (Korzus, 2010; Wood et al., 2005; Alarcon et al.,
2004; Giralt et al., 2011). Korzus et al. (2010) generated transgenic mice with eliminated
HAT function of CBP (cAMP-responsive element binding protein). The results indicated
the consolidation of short-term memory to long-term memory in these mice was
impaired, and suppression of transgene expression or administration of HDAC inhibitor
Trichostatin A restored the long-term memory formation (Korzus et al., 2004). Similarly,
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several other studies demonstrated CBP is involved in, and plays a critical role in longterm memory formation (Wood et al., 2005; Vecsey et al., 2007; Barrett et al., 2011).
A Rubinstein-Taybi (R-T) syndrome mouse model with less than normal expression
of CBP was used by Alarcon et al. to examine the effect of histone deacetyltransferase
inhibitors on mental retardation. These researchers found that inhibitors of histone
deacetyltransferase could reverse the mental retardation typical for mice with R-T
syndrome, offering evidence that this syndrome may result from the abnormal epigenetic
histone acetylation function of CBP (Alarcon et al., 2004). Similarly, Giralt et al. (2011)
demonstrated reduced hippocampal expression of CBP and lower level of histone H3
acetylation for heterozygous Huntington’s disease knock-in mutant mice (Hdh Q7/Q111)
compared to wild type mice. Administration of histone deacetylase inhibitor Trichostatin
A helped to rescue memory deficits in these Hdh Q7/Q111 mice. These studies are
significant because they implicated the promising role of epigenetic regulation in the
treatment of innate mental diseases.
It is important to note that DNA methylation and histone acetylation may work in
concert to regulate long-term memory formation and synaptic plasticity. Miller et al.
(2008) found that DNA methyltransferase inhibition blocks memory and memoryassociated acetylation, while increasing histone acetylation before administering DNA
methyltransferase inhibitor can prevent memory deficits. A methyl-CpG-binding protein,
MeCP2, has been reported to function as the medium that connects DNA methylation and
histone acetylation (Martinowich et al., 2003; Nan et al., 1998; Kokura et al., 2001).
MeCP2 encodes a 486-amino-acid protein with three recognizable domains: the methyl-
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CpG-binding domain (MBD) that mediates methyl-CpG-binding, a C-terminal domain,
and the transcriptional repression domain (TRD) that recruits corepressor complexes
Sin3A, c-Ski and N-CoR (Chahrour & Zoghbi, 2007). These complexes contain HDAC
components that function in chromatin remodeling (Shahbazian et al., 2002). Mutations
in MeCP2 cause Rett syndrome, a postnatal progressive neurodevelopmental disorder
characterized by reversal of speech, gradual loss of motor skills and mental impairments
(Chahrour & Zoghbi, 2007). Evidence suggests that mutations in MeCP2 lead to
abnormal histone acetylation; both may play a role in Rett syndrome (Shahbazian et al.,
2002).
For cancer patients suffering from cognitive decline especially memory loss induced
by chemotherapy, these above pioneering studies suggest the possibility that epigenetic
modifications can modify certain gene expression of brain neurons to protect or retrieve
the ability to remember (Levine, 2008). Increased knowledge of the interaction between
epigenetics and neuronal functions could identify intervention(s) that could modify
epigenetics to alleviate or diminish memory loss associated with chemotherapy.

1.2.3 Anti-cancer and Neuro-protective Effects of Berries
There is evidence suggesting edible small and soft-fleshed berry fruits may have
beneficial effects against several types of human cancers. Berry phytochemicals may
also potentially sensitize tumor cells to chemotherapeutic agents by inhibiting pathways
that lead to treatment resistance. In addition, berry fruit consumption may provide
protection from therapy-associated toxicities (Seeram, 2008). That is, berries can inhibit
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the growth of cancer cells and at the same time protect other normal cells including
neurons. From this point of view, berries have the potential to be the perfect natural
solution to chemotherapy induced cognitive decline.
Anti-cancer effects of berries are well established. Some of the known constituents
in berries that exhibit cancer-preventive effects include vitamins A, C, E and folate acid;
minerals calcium, selenium and zinc; especially phenolic molecules such as
anthocyanins, flavonols, flavanols, proanthocyanidins, ellagitannins, and phenolic acids
(Seeram, 2008). Six popularly consumed berries (blackberry, black raspberry, blueberry,
cranberry, RR and strawberry) were evaluated for their phenolic constituents’ ability to
inhibit the growth of human cancer cell lines. These included oral (KB, CAL-27), breast
(MCF-7), colon (HT-29, HCT116), and prostate (LNCaP) tumor cell lines at berry
concentrations ranging from 25 to 200 µg/mL (Seeram et al., 2006). The inhibition of
cell proliferation in all the cell lines was dependent on the concentration of berry extracts.
Black raspberry and strawberry extracts also showed the most significant pro-apoptotic
effects against colon cancer cell line HT-29 (Seeram et al., 2006).
Kresty et al. (2001) evaluated the inhibitory effects of lyophilized black raspberries
against N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in the
F344 rats (known for good reproductive performance, big litters, and low levels of
aggression toward handlers) in the carcinogenesis initiation phase and post initiation
phase (Holmes, 2003). They found that feeding rats with lyophilized black raspberries
significantly reduced tumor incidence, multiplicity, proliferation and preneoplastic lesion
formation. Different dosages showed significance at different phases of tumorigenesis.
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Strawberries were also shown to be effective in the inhibition of NMBA induced
tumorigenesis in the rat esophagus (Carlton et al., 2001). However, blueberries were
shown to have no protective effect against chemical carcinogen (Aziz et al., 2002). One
possible explanation could be blueberries do not contain as much ellagic acid, a member
of ellagitannins most abundant in raspberries and able to reduce DNA damage by
alkylation (Mandal & Stoner, 1990; Duthie, 2007).
Although ellagic acid has been shown to be an important factor in the inhibition of
carcinogenesis, it is clear that other compounds also contribute to this observed inhibitory
effect. Xue et al. (2001) examined the anti-malignant transformation activity of several
extracts from freeze-dried strawberries and black raspberries. They found that both
ellagic acid and methanol extracts from both types of berries caused decreased malignant
transformation in a dose-dependent manner. The mechanisms for the inhibition of cell
transformation involve the interaction of berry extracts with DNA binding and repair.
Since methanol extracts do not contain detectable amounts of ellagic acid, there must be
other chemicals producing the geno-protective effect (2001).
Based on these positive results for black raspberries, researchers have extensively
used them in research to illustrate their benefits against chemically induced esophageal
and colon cancer (Chen et al., 2006a; Chen, Rose, Hwang, Nines, & Stoner, 2006b; Reen,
Nines, & Stoner, 2006). To elucidate the molecular mechanisms involved in
chemoprevention by black raspberries, Lu et al. (2006) employed the mouse epidermal
CL 41 cell line to look at the targeted genes and involved transcription factors. They
postulated that the inhibition takes effect by mediating the signaling transduction
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pathways leading to activation of proteins AP-1 and NFkB, subsequently resulting in
down-regulation of VEGF and COX-2 expression. Contrary to some of the previous
explanations (Stoner et al., 1990; Duthie, 2007), Lu’s group showed methanol-extracted
fraction to be the major fraction responsible for the inhibitory activity of black
raspberries (Lu, Li, Zhang, Stoner, & Huang, 2006). This contradiction again illustrates
the unclear understanding of berry constituents, which is an important reason for the use
of whole natural berries instead of the extracts of constituents.
Although there is clear evidence that berries can act against carcinogenesis in vitro
and in vivo using animal models, the confirmation in humans has not been well
established. A pilot study done by Kresty et al. (2006) examined the chemo-preventive
effects of black raspberries on patients with Barrett’s esophagus, a premalignant
esophageal condition that significantly increases the risk of patients to develop
esophageal adenocarcinoma. The preliminary results of 10 patients in Kresty’s study
showed daily consumption of lyophilized black raspberries promotes reduction of two
markers of oxidative stress in the urinary excretion of the patients (Kresty et al., 2006).
Polyphenols widely present in berries have been reported to have neuro-protective
effects (Shin, Park, & Kim, 2006; Kang et al., 2006; Ramiro-Puig et al., 2009; Joseph et
al., 2009; Fortalezas et al., 2010; Pannangrong, Wattanathorn, Muchimapura, Tiamkao, &
Tong-un, 2011). For example, Bastianetto et al. (2009) have shown that in vitro,
resveratrol protects hippocampal cells against β-amyloid induced toxicity, a key factor in
the pathway of developing Alzheimer’s disease (AD).
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Shin et al. (2006) looked at the protective effects of anthocyanins against focal
cerebral ischemic injury in rats. The pre-treatment of anthocyanins significantly reduced
the brain infarct volume and TUNEL positive cells that were induced by middle cerebral
artery occlusion and reperfusion. They also suggested that anthocyanins reduced neuronal
damage caused by focal cerebral ischemia by blocking the JNK and p53-signalling
pathway. Kang et al. (2006) investigated the neuro-protective effects of cyanidin-3-O-βD-glucopyranoside (C3G), an aglycon of anthocyanin from the mulberry fruits on
neuronal cell damage. They found that the C3G extract inhibited the cerebral ischemic
damage caused by oxygen glucose deprivation in vivo.
Of particular interest to this dissertation research are the anti-cancer and neuroprotective effects of RR (Rubus idaeus). Research from this lab indicates unfractionated
aqueous RR extract can significantly inhibit mutagenesis by direct-acting and
metabolically activated carcinogens, and inhibit cancer cell proliferation. This effect is
not all due to the antioxidant activity of RR, but the combination of all the characteristics
of berry extracts (Wedge et al., 2001; Smith et al., 2004; Tate et al., 2003; Tate et al.,
2004; Seeram et al., 2006; God et al., 2010). This dissertation study in our lab is the first
research that specifically looks at neuro-protective effects of unfractionated aqueous RR
in chemotherapy-treated neurons.
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CHAPTER TWO MATERIALS AND METHODS
This chapter provides a description of materials, experimental designs, experimental
procedures, measurements, and statistics used in this dissertation study.
The rat PC12 pheochromocytoma cell line (CRL-1721) obtained from American
Type Culture Collection (ATCC) (Manassas, VA) was used as a cell model in this study.
This cell line exhibits neuronal behavior when grown in the presence of NGF and is
considered a standard cell model for neuronal study (Adler, Gough, & Blundon, 2006).
Cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium from
ATCC supplemented with 5% heat-inactivated horse serum from Atlanta Biologicals
(Atlanta, GA), 10% fetal calf serum from Atlanta Biologicals and 1%
penicillin/streptomycin from Sigma Aldrich (St. Louis, MO) at 37 °C, in a 5% CO2
humidified incubator till treated (2006).
Doxorubicin hydrochloride was obtained from Sigma Aldrich. As instructed by the
manufacturer, the drug was dissolved in Dimethyl Sulfoxide (DMSO) to 100 µM and
refrigerated at 4°C until used to treat PC12 neuronal cells (Sigma Aldrich, 2012).
Freeze-dried RR were obtained from the Meeker Variety at Van Drunen Farms
(Momence, IL). Five grams of berries were placed into 35mL of distilled water and then
centrifuged 10 minutes at 3000rpm. The supernatant was removed and centrifuged for an
additional 10 minutes at 3000rpm. This process was repeated, and the final supernatant
sterilized through a 0.20-µm-pore-size filter from Nalgene Labware (Rochester, NY).
The sterilized RR extract was then digested and refrigerated at 4°C until used to treat
PC12 neuronal cells (See Appendix B for Digestion Protocol).
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2.1

Effects of Doxorubicin on Metabolic Activity of PC12 Neuronal Cells
The objective of this experiment was to evaluate the effects of DOX chemotherapy

on metabolic activity of NGF induced PC12 neuronal cells. As shown in Figure 2.1, 48
hours prior to treatments, PC12 cells were plated in 96-well plates coated with collagen
from Sigma (See Appendix B for Collagen Coating Protocol) at a density of 1×105
cells/well (Adler et al., 2006). Plated cells were maintained in 1:5 diluted serum with 100
ng/mL of NGF from Sigma in RPMI (Adler et al., 2006). Treatments were a 48-hour
incubation of NGF induced PC12 neuronal cells in 1:5 diluted medium and serum with
various doses of DOX (0.001µM, 0.01µM, 0.1µM, 1µM, 10µM).
Metabolic activity of PC12 neuronal cells was assessed using the CellTiter
96®Aqueous Non-Radioactive Cell Proliferation Assay from Promega (Madison, WI).
This colorimetric assay converts (3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS), a tetrazolium
compound, into formazan that is soluble in tissue culture medium by dehydrogenase
enzymes found in metabolically active cells. Formazan absorbance at 490 nm is directly
proportional to the number of metabolically active cells in the sample. After treating the
plate with working solution, MTS and RPMI plus serum with a ratio of 1:5, it was
incubated for 2-4 hours at 37 °C, in a 5% CO2 humidified incubator. Absorbance at
490nm was measured using the Tecan Infinite m200 microplate reader (Durham, NC).
MTS data was analyzed using standard statistical program in Microsoft Excel. In
each experiment, culture plates were done in octuplets. For each condition, the counts
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were averaged. Because the number of control colonies varied slightly from one
experiment to another, the data for each experiment were normalized to the average of
controls for that experiment. Three independent plates for each set of experiment were
completed on different days. The nomalized data were then averaged from the three
independent plates. The MTS data were compared by two-tail Student t-test, with p
<0.05 considered statistically significant. Unless otherwise described, all MTS data was
analyzed using this methodology.

2.2

Effects of in Vitro Digested Red Raspberry on Metabolic Activity of PC12

Neuronal Cells
The objective of this experiment was to evaluate the effects of in vitro digested RR
on metabolic activity of NGF induced PC12 neuronal cells. As shown in Figure 2.2, 48
hours prior to treatments, cells were plated in 96-well plates coated with collagen at a
density of 1×105 cells/well. Plated cells were maintained in 1:5 diluted medium and
serum with 100 ng/mL of NGF. Treatments were a 48-hour incubation in 1:5 diluted
medium and serum with various percentages of digested RR (0.0625%, 0.125%, 0.25%,
0.5%, and 1%). The metabolic activity was assessed as described in Section 2.1.

2.3

Effects of in Vitro Digested Red Raspberry on Metabolic Activity of

Doxorubicin Treated PC12 Neuronal Cells
The objective of this experiment was to look at the effects of in vitro digested RR on
metabolic activity of DOX treated PC12 neuronal cells. As shown in Figure 2.3, 48

29

hours prior to treatments, the cells were plated in 96-well plates coated with collagen at a
density of 1×105 cells/well. Plated cells were maintained in 1:5 diluted medium and
serum with 100 ng/mL of NGF. Two different concentrations of DOX, one percentage of
digested RR, and the combination of them were added to growth medium of NGF
induced PC12 neuronal cells. Specifically, cells were treated with DMSO, 0.1% digested
RR, 1µM of DOX, 0.1µM of DOX, the combination of 0.1% digested RR and 1µM of
DOX, and the combination of 0.1% digested RR and 0.1µM of DOX. Forty-eight hours
after treatment, metabolic activity was measured as described in Section 2.1.

2.4

Effects of in Vitro Digested Red Raspberry on Neurite Growth of

Doxorubicin Treated PC12 Neuronal Cells
The objective of this experiment was to look at the effects of in vitro digested RR on
neurite growth of DOX treated PC12 neuronal cells.
As shown in Figure 2.4, 48 hours prior to treatments, cells were plated in 96-well
plates coated with collagen at a density of 1×104 cells/well. Plated cells were maintained
in 1:5 diluted medium and serum with 100 ng/mL of NGF. Two different concentrations
of DOX, one concentration of digested RR, and the combination were added to growth
medium of NGF induced PC12 neuronal cells. Specifically, cells were treated with
DMSO, 0.1% digested RR, 1µM of DOX, 0.1µM of DOX, the combination of 0.1%
digested RR and 1µM of DOX, and the combination of 0.1% digested RR and 0.1µM
Molar of DOX. Pictures of neurite growth of PC12 neuronal cells were taken using
Canon Powershot S5 IS digital camera on a MEIJI TECHNO TC5300 microscopy with
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CAMEROWINDOW software at a magnification of 800. Each picture depicted the spot
with the greatest number of neurites for each sample.

2.5

Effects of Human Plasma Collected Prior to and After Red Raspberry

Consumption on Doxorubicin Treated PC12 Neuronal Cells
The objective of this experiment was to look at the effects of human plasma prior to
and after RR consumption on DOX treated PC12 neuronal cells. Human blood plasma
from a previous IRB approved study was used to treat NGF induced PC12 neuronal cells
(See Appendix C for IRB approval). In a previous study (Romero, 2011), freeze-dried
RR were given to 16 healthy volunteers whose eligibility was determined by a diet and
health questionnaire. Participants were asked to refrain from eating fruits, fruit-related
foods or juices for two days. Blood was drawn prior to the consumption of freeze-dried
RR, and 2-4 hours after consumption of 2 cups/day of RR with their regular diet for 3.5
days. Plasma was seperated from the blood and stored in -20 °C freezer until used to
treat PC12 neuronal cells. Plasma from 6 of 18 participants were selected to treat cells
since questionnaires showed it to be free of known interfering factors such as curry
intake, supplement intake and menses.
As shown in Figure 2.5, 48 hours prior to treatments, PC12 cells were plated in 96well plates coated with collagen at a density of 1×105 cells/well. Plated cells were
maintained in RPMI and 15% autologous human plasma with 100 ng/mL of NGF.
Treatments were a 48-hour incubation in DMSO control, DMSO plus doxorubicin
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control, and combinations of 15% autologus human plasma ( pre-plasma or post-plasma)
and 1µM of DOX. Metabolic activity was measured as described in Section 2.1.

2.6

Effects of Doxorubicin, in Vitro Digested Red Raspberry and Combination

on DNA Methylation of PC12 Neuronal Cells
The objective of this experiment was to compare the effects of DOX, in vitro
digested RR and their combinations on DNA methylation of NGF induced PC12 neuronal
cells. As shown in Figure 2.6, 72 hours prior to treatments, the PC12 cells were added to
culture flasks coated with collagen at a density of 5×105 cells/plate. Plated PC12 cells
were maintained in 1:5 diluted medium and serum with 100 ng/mL of NGF. One
concentration of DOX, one percentage of digested RR, and the combination of them were
added to growth medium of NGF induced PC12 neuronal cells. Specifically, NGF
induced PC12 neuronal cells were treated with DMSO, 0.1% digested RR, 1µM of DOX,
and the combination of 0.1% digested RR and 1µM of DOX. Seventy-two hours after
treatments, the PC12 neuronal cells were harvested, suspended in phosphate buffered
saline (PBS) and stored in -20°C freezer until DNA isolation.
DNA isolation was performed using the QIAamp DNA mini kit from QIAGEN
(Valencia, CA). Briefly, lysis buffer was added to treated PC12 neuronal cells. The
mixture was then transferred to a pin column to bind DNA. After washing several times
with wash buffer, purified DNA was eluted and harvested into a micro-centrifuge tube.
The concentration of DNA in each sample was measured using NanoDrop 2000
spectrophotometer from Thermo Scientific (Pittsburgh, PA). All samples were adjusted
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to the same final DNA concentration by adding Polymerase Chain Reaction (PCR) water
from Promega (Madison, WI).
Bisulfite treatment was performed using EpiTect Bisulfite Kit from QIAGEN
(Valencia, CA). Approximately 1 µg of DNA sample was diluted with dilution buffer
and incubated for 6 hours in freshly prepared CT Conversion Reagent. Only
unmethylated cytosine should be converted to uracil. Methylated cytosine should remain
unchanged. After treatment, the mixture was passed through a pin column to bind DNA
and washed several times with wash buffer. Finally, bisulfite treated DNA was recovered
by adding elution buffer and stored in -20 °C until use. The sample concentration of
bisulfite treated DNA was measured using NanoDrop 2000 spectrophotometer. Bisulfite
treated DNA samples were adjusted to the same final concentration with PCR water.
A pair of primer sets was designed to amplify either methylated or unmethylated
DNA based on the difference between their sequences after bisulfite treatment. Primers
are designed using the online tool, Meth Primer (Li & Dahiya, 2002), and ordered from
eurofins (Mebane, NC). Highly methylated rat genomic DNA from Epigendx
(Worcester, MA) was used to test the validity of primers for methylated DNA. As shown
in Table 2.1, methylated-specific primers and unmethylated-specific primers for BDNF,
CREB, EGR1, FOS, Nr3C1, TNF, and Tp53 genes were designed. Among these, primers
for BDNF, EGR1, and FOS genes were verified to work in PCR (listed bold in Table
2.1), while the other primers for CREB, TNF, Nr3C1 and Tp53 did not yield products in
PCR.
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The PCR mixture, which was made up to 20µL with PCR water, contained bisulfitetreated DNA (2µM), forward primer (2.5µM), reverse primer (2.5µM), Taq master mix
from Promega (10µM). Reaction was performed in a thermo cycler with the settings of 1
cycle at 95°C for 10 min, 40 cycles at 95°C for 15 sec, 59°C for 30 sec, and 10°C till use.
Three repeats for samples from different days were performed for each primer set. The
concentration of PCR products in each sample was measured using NanoDrop 2000
spectrophotometer. All DNA samples were then adjusted to the same final concentration.
PCR products were analyzed by electrophoresis through a Mini ReadyAgarose
Electrophoresis Gel 161-3006 from Bio -Rad (Hercules, CA) with TBE and 3% agarose
plus ethidium bromide to determine the methylation status of the DNA.
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CHAPTER THREE RESULTS
This chapter describes results corresponding to each experiment described in
Chapter Two. All MTS data were compared by two-tail Student t-test as described in
Section 2.1, with p < 0.05 considered statistically significant.

3.1

Effects of Doxorubicin on Metabolic Activity of PC12 Neuronal Cells
The cells were cultured in plates for 48 hours in the presence of various amounts of

DOX and their metabolic activity were measured as described in Section 2.1. Since DOX
was dissolved in DMSO, a DMSO control was also included. As shown in Table 3.1 &
Figure 3.1, the metabolic activities of PC12 neuronal cells treated with various
concentrations of DOX were all statistically different from the DMSO control (p < 0.05).
Compared to control, as low as 0.001µM of DOX reduced the metabolic activity of PC12
neuronal cells by over 10% with statistical significance (p = 0.032). With the increase of
the concentration of DOX from 0.001µM to 1µM, the metabolic activity decreased
gradually. Metabolic activity decreased abruptly when the concentration of DOX is
greater than 1µM (p = 0.017).

3.2

Effects of Digested Red Raspberry on Metabolic Activity of PC12 Neuronal

Cells
PC12 neuronal cells were cultured in plates for 48 hours in the presence of various
amounts of in vitro digested RR and their metabolic activity were measured as described
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in Section 2.2. Since digested RR was dissolved in water, a water control was also
included. As shown in Table 3.2 & Figure 3.2, there was a trend of increased metabolic
activity for 0.0625% to 0.5% digested RR treated PC12 neuronal cells and decreased
metabolic activity for 1% of in vitro digested RR treated PC12 neuronal cells compared
to control.

3.3

Effects of in Vitro Digested Red Raspberry on Metabolic Activity of

Doxorubicin Treated PC12 Neuronal Cells
PC12 neuronal cells were treated with 0.1% in vitro digested RR, 0.1µM and 1µM
of DOX, and their combinations as described in Section 2.3. As shown in Table 3.3 &
Figure 3.3, the mean metabolic activity of PC12 neuronal cells treated with combinations
of in vitro digested RR and DOX (1.178 & 1.088) were higher compared to that of cells
treated with DOX alone (0.966 & 0.897) (p = 0.035 & 0.057 respectively). With
increased concentration of DOX from 0.1µM to 1µM, the mean differences between
metabolic activities of PC12 neuronal cells treated with and without in vitro digested RR
decreased from 0.212 to 0.191.

3.4

Effects of in Vitro Digested Red Raspberry on Neurite Growth of

Doxorubicin Treated PC12 Neuronal Cells
PC12 neuronal cells were treated with 0.1% in vitro digested RR, 0.1µM and 1µM
of DOX, and their combinations as described in Section 2.4. The representative neurite
growth of NGF induced PC12 neuronal cells is illustrated in Figure 3.4. The labels of the
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pictures A-F correspond to A-F in Figure 3.3. Cells treated with in vitro digested RR had
more neurite connections compared to control cells treated with DMSO. It appears that
cells treated with digested RR plus DOX had increased neurite connections compared to
cells treated with DOX alone, but a more extensive set of experiments must be done to
confirm this.

3.5

Effects of Human Plasma collected prior to and After Red Raspberry

Consumption on Doxorubicin Treated PC12 Neuronal Cells
The effect of in vivo human metabolized RR as a neuroprotectant against neurotoxicity of
DOX was evaluated by comparing PC12 neuronal cells treated with human plasma collected
prior to freeze-dried RR consumption (pre-plasma) to cells treated with human plasma collected
after freeze-dried RR consumption (post-plasma). PC12 neuronal cells were treated with 1µM of
DOX, 15% pre-plasma, 15% post-plasma, and DOX plus plasma as described in Section 2.5 .
The metabolic activity ratio for PC12 neuronal cells treated with plasma plus DOX to PC12
neuronal cells treated with plasma alone was calculated for both pre-plasma and post-plasma. As
shown in Figure 3.5, the ratio for pre-plasma and post-plasma was compared for each participant.
A higher ratio for post-plasma compared to pre-plasma can indicate the effectiveness of in vivo
metabolized RR as a neuroprotectant against DOX chemotherapy.
The calculated ratios for post-plasma of participants #1-#4 were higher compared to ratios
of their pre-plasma, while the calculated ratios for post-plasma of participants #5-#6 were lower
compared to ratios of their pre-plasma. The average ratio of post-plasma for six participants was
higher than that of pre-plasma with no statistical significance. The differences between post-

37

plasma ratio and pre-plasma ratio calculated by dividing post-plasma ratio by pre-plasma ratio
for each donor (#1-#6) are: 1.34, 1.19, 1.12, 1.05, 0.79, 0.84.

3.6

Effects of Doxorubicin, in Vitro Digested Red Raspberry and Combination

on DNA Methylation of PC12 Neuronal Cells
Methylation specific PCR (MSP) primers for EGR1, NR3C1/GR, BDNF, TNF,
Tp53, CREB, and FOS genes were designed. Methylated-specific primers for BDNF,
EGR1, and FOS were verified to work in MSP using highly methylated rat genomic
DNA. Highly methylated rat genomic DNA is in vitro enzymatically methylated
genomic DNA that serves as positive control in DNA methylation analysis. As shown in
Figure 3.6, among the seven screened genes, BDNF, EGR1, and FOS showed
methylation bands on electrophoresis gels for highly methylated rat genomic DNA,
indicating these designed methylated-specific primers can be used in MSP. In Figure 3.7,
BDNF, EGR1, and FOS showed unmethylated bands for DNA of PC12 neuronal cells,
indicating these designed unmethylated-specific primers can be used in MSP.
Verified methylated-specific and unmethylated-specific primers were used to screen
methylation pattern of DNA from the control and treated PC12 neuronal cells by MSP.
As shown in Table 3.4, the methylation pattern of EGR1 and BDNF is the same for DNA
of control, DOX treated, digested RR treated, and combination treated PC12 neuronal
cells; methylation pattern of FOS changed for DNA of DOX and combination treated
PC12 neuronal cells compared to control and in vitro digested RR treated cells.
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As shown in Figure 3.8, FOS showed unmethylated bands on electrophoresis gel for
DNA from PC12 neuronal cells, indicating the designed unmethylated-specific primers
worked in MSP; FOS showed methylated bands on electrophoresis gel for highly
methylated rat genomic DNA, indicating the designed methylated-specific primers
worked in MSP. As shown in Figure 3.9, using verified FOS methylated-specific primers
and unmethylated-specific primers in MSP for DNA from the control and treated PC12
neuronal cells harvested from three different days, DNA of DOX treated and combination
treated PC12 neuronal cells showed a different methylation pattern compared to DNA of
control and digested RR treated PC12 neuronal cells. Specifically, all the DNA from
control and treated PC12 neuronal cells has unmethylated FOS gene, and only DNA of
DOX treated and combination treated PC12 neuronal cells has methylated FOS gene. As
shown in Table 3.5, screening of methylation pattern of FOS gene for DNA from the
control and treated PC12 neuronal cells harvested from seven different days indicates that
not all the PC12 neuronal sample sets have methylated FOS gene for DOX treated and
combination treated cells. However, as shown in Figure 3.10, a majority of the screened
sample sets showed a difference in the methylation pattern of FOS for DNA from DOX
treated and combination treated PC12 neuronal cells compared to the control and in vitro
digested RR treated cells.
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CHAPTER FOUR DISCUSSION
This chapter focuses on interpretation of results of this dissertation research in light
of other published results. Special attention will be on dosage and mechanisms for
neuronal toxicity of DOX, possible mechanisms for the protective effects of red raspberry
from neurotoxicity induced by DOX, variability of protective effects of RR in vivo, and
DNA methylation changes associated with DOX treatment in PC12 neuronal cells.

4.1

Dosage and Mechanisms for Neuronal Toxicity of Doxorubicin
This study showed as little as 0.001µM of DOX reduced the metabolic activity of

PC12 neuronal cells by over 10% (p < 0.05 by student t-test) (Figure 3.1). Dietrich and
colleagues also showed in vitro and in vivo that lower dosages of chemotherapy agents
were needed to cause neuronal cell death compared to dosages needed for tumour cell
death (Dietrich, Han, Yang, Mayer-Proschel, & Nobel, 2006). These results are clinically
significant because historically most of the chemotherapy drugs are not believed to be
capable of crossing the blood-brain barrier, but revealing research indicates the genetic
variability in drug transporters in the blood-brain barrier and pharmocogenetic factors
may allow minute leakage of toxic chemotherapy into delicate brain neurons (Ahles &
Saykin, 2007). This minute amount of leak might be enough to cause abnormalities of
brain neurons, yielding a reduction in metabolic activity of brain neuronal cells.
In addition, this present study indicates greater than 1µM of DOX treatment is
associated with an abrupt decrease in PC12 neuronal cell metabolic activity (Figure 3.1).
With increased concentration of DOX from 0.1µM to 1µM, the differences between
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metabolic activity of PC12 neuronal cells treated with and without digested RR decreased
(Figure 3.3). This indicates at higher concentrations of DOX, the mechanism for the
decrease of PC12 neuronal cell metabolic activity may have shifted. Lopes and
colleagues found similar results specifying for concentrations up to around 0.5µM, cell
death follows an apoptotic pattern, while for higher concentrations, apoptosis is inhibited
and necrosis becomes dominant (Lopes et al., 2008). Another study indicates that DOX
has the capacity to cause apoptotic neuronal cell death by disturbing mitochondrial
respiration. It reports that DOX administration can increase levels of pro-apoptotic
proteins Bax and p53 in brain mitochondria of mice. As shown in Figure 4.1, protein
Bax forms complex with p53 leading to cytochrome c release to activate caspase 3 and
initiate programmed neuronal cell death (Tangpong et al., 2006). The present study
suggests that RR may only protect the PC12 neuronal cells from apoptosis caused by
minute amount of DOX, not necrosis caused by higher amount of DOX.
Other mechanisms responsible for the toxic effects of DOX on neuronal functions
are proposed to be drug-induced free radical mediated oxidative stress, metabolized
products that can pass the blood-brain barrier, and DNA damage. First, DOX can
increase protein oxidation, protein nitration, lipid peroxidation, and DNA/RNA oxidation
by generating super-oxide radical O2- (Butterfield & Kanski, 2001; Cardoso et al., 2008;
Joshi et al., 2005; Joshi et al., 2007; Muller, Jenner, Bruchelt, Niethammer, & Halliwell,
1997; Tangpong et al., 2007). As shown in Figure 4.2, super-oxide radical O2participates in redox cycling activated by nitric oxide synthase and cytochrome P450, and
reacts with H2O2 and other reactive species to produce reactive oxygen species (ROS)
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and reactive nitrogen species (RNS), leading to oxidative damages with neuronal
dysfunction and neuronal cell death (Halliwell & Gutteridge, 1999; Gutierrez, 2000;
Deres et al., 2005). Increased levels of oxidation have been observed in brains of
different types of mice with mild cognitive decline induced by DOX (Joshi et al., 2005;
Tangpong et al., 2007; Cardoso et al., 2008). The brain is thought to be particularly
vulnerable to oxidative stress because of: 1) large component of polyunsatrurated fatty
acids; 2) elevated oxygen demand; and 3) relatively low antioxidant capacity (Joshi et al.,
2007; Aluise et al., 2010). These results could indicate that oxidative stress may be a
mechanism causing cognitive impairments in cancer patients treated with DOX
chemotherapy.
Furthermore, DOX induces cytokine (such as tumor necrosis factor alpha, TNF-α)
production, which can pass through the blood-brain barrier and stimulate local cytokine
production, inflammation, and oxidative stress (Tangpong et al., 2006; Aluise et al.,
2010). In the brain, TNF-α can activate local cytokine production and generates nitric
oxide synthase (NOS) (Szelenyi, 2001). NOS is the enzyme important in the generation
of nitric oxide (NO), one of reactive nitrogen species (RNS) (Tangpong et al., 2007)
(Figure 4.3). Nitric oxide is involved in nitration of proteins in mitochondria, such as
MnSOD, leading to accumulation of O2- and further oxidative stress (Tangpong et al.,
2007).
Finally, as shown in figure 4.4, DOX can intercalate into DNA, inhibit
topoisomerase II, preventing replication and cell growth, leading to DNA breaks and cell
death. Although DOX interacts with other cellular targets, the interaction with DNA is
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believed essential for its effects (Frederick et al., 1990). It has been reported that DOX
binds DNA sequence CGATCG to inhibit micromolecular biosynthesis (Frederick et al.,
1990; Momparler, Karon, Siegel, & Avila, 1976). Doxorubicin prevents unwinding of
DNA for replication by interacting with helicases, and leads to DNA breaks by inhibiting
topoisomerase II religation activity. (Bachur et al., 1992; George, Ghate, Matson, &
Besterman, 1992; Sander & Hsieh, 1983; Tewey, Rowe, Yang, Halligan, & Liu, 1984).
Taken together, minute amounts of DOX decreased metabolic activity of PC12
neuronal cells in vitro. With higher concentration of DOX, the mechanism for the
decrease of neuronal cell activity may have shifted from apoptosis to necrosis. Several
mechanisms may account for this effect including direct neuronal toxicity, initiation of
the apoptotic pathway, stimulation of cytokine production and oxidative stress, and
interaction with DNA. As shown by the results of this study, the interaction between
DOX and DNA may be not limited to intercalation and replication interference.
Epigenetics may play a role to influence specific gene expression and sebsequent
neuronal cell functions.

4.2

Possible Mechanisms for the Protective Effects of Red Raspberry from

Neurotoxicity Induced by Doxorubicin
Red raspberry (Rubux idaeus L.) is an economically important berry crop with high
levels of antioxidants and complex mixtures of phytochemicals that provide protective
health benefits through a combination of additive and/or synergistic effects (de Ancos et
al., 2000; Anttonen & Karjalainen, 2005; Joseph et al., 2009).
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This present study revealed low percentages of in vitro digested RR alone increased
the metabolic activity of PC12 neuronal cells without statistical significance (Figure 3.2).
In vitro digested RR counteracted the neurotoxic effects of low concentrations of DOX
chemotherapy in PC12 neuronal cells including decreased metabolic activity (Figure 3.3)
and fewer neurite connections (Figure 3.4). These data emphasize results from other
studies showing that berries display neuroprotective effects in various in vitro and in vivo
models of toxicity (Shin et al., 2006; Kang et al., 2006; Ramiro-Puig et al., 2009; Joseph
et al., 2009; Fortalezas et al., 2010; Pannangrong et al., 2011). They also suggest RR
consumption may be a potential natural intervention to protect against chemotherapy
induced cognitive decline.
As shown in Figure 4.5, the mechanisms responsible for the neuroprotective effects
of RR against DOX chemotherapy likely include the high antioxidant activity,
involvement in anti-inflammatory/anti-stress signaling pathways, inhibition of apoptotic
pathways, and genoprotective effect of phenolic compounds in berries (Barros et al.,
2006; Kang et al., 2006; Shin et al., 2006; Joseph et al., 2009; Fortalezas et al., 2010;
Pangnangrong et al., 2011).
Phenolics are classified by their structural characteristics into several categories
including flavonoids (flavanols/catechins, flavonols, flavones, flavanones, isoflavonoids,
anthocyanins), phenolic acids, stilbenes, tannins, and lignans (Alwerdt et al., 2008; Han
et al., 2007; Liu et al., 2002; Paredes-López, Cervantes-Ceja, Vigna-Perez, & HernandezPerez, 2010). These phenolic compounds are known to provide a variety of health
benefits including antioxidant, anti-allergic, anti-carcinogenic, antimicrobial, anti-
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mutagenic and anti-inflammatory effects (Benavente-Garcia, Castillo, Marin, Ortuno, &
Rio, 1997; Do, Kang, Kim, Jo, & Lee, 2004; Kim, Heo, Kim, Yang, & Lee, 2005;
Murakami et al., 2000; Wang, Provan, & Heliwell, 2000; Yoshimura, Nakazawa, &
Yamaguchi, 2003).
High amounts of total phenolic compounds especially anthocyanins, ellagic acid,
flavonols, and stilbenes in RR contribute to their capacity to scavenge free radicals
(Wang and Lin, 2000; Liu et al., 2002). As many as 11 anthocyanins have been
identified in raspberries (de Ancos, Gonzales, & Cano, 1999; Mullen et al., 2002).
Anthocyanins are hydrophilic pigments that introduce red or purple colors to fruits,
vegetables and rice (Pannangrong et al., 2011). The properties of anthocyanins have been
reported to include the chelation of metal ions, inhibition of lipid oxidation, impact on
cell cycling, suppression of tumors, modulation of signal transduction and apoptosis,
detoxifying enzymes and metabolism, and scavenging of free radicals (Chun, Kim, &
Lee, 2003; Kim et al., 2004; Liu et al., 2002; Han et al., 2007; Wang et al., 1997;). For
example, Kang et al. (2006) concluded cyaniding-3-glucoside, a major anthrocyanin,
helps to protect PC12 neuronal cells from H2O2 induced oxidative damage. As
mentioned in Section 4.1, H2O2 reacts with DOX induced O2- leading to oxidative
damages to neuronal cells. In addition, anthocyanins can be absorbed by brain
enthothelial cell lines, and potentially cross the blood-brain barrier (Youdim et al., 2003).
Therefore, anthocyanins may play a role in the neuroprotective effect of RR against DOX
chemotherapy in vitro, and possibly in vivo.
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Ellagic acid, another phenolic compound, is commonly found as ellagitannins with
high concentrations in raspberries (Anttonen & Karjalainen, 2005). It has been shown to
have antioxidant activity, anticarcinogenic and vasodilation properties (Mullen et al.,
2002). Flavonols, such as quercetin and kaempferol, are powerful antioxidants with a
role in the neuro-protective effects of berries (Knekt et al., 2002; Hubbard et al., 2003).
Stilbenes such as resveratrol, pterostilbene, and piceatannol all possess anti-aging, and
anti-oxidant activities (Joseph, Fisher, Cheng, Rimando, & Hale, 2008; Matsuda et al.,
2000; Mizuno, Schrader, & Rimando, 2008; Park, Choo, Yoon, & Kim, 2002; Shakibaei,
Harikumar, & Aggarwal et al., 2009; Wang, Catana, Yang, Roderick, & Van Breemen,
2002).
Though each mentioned individual bioactive compound could be responsible for the
high antioxidant activity of RR, the interactive effects of all the compounds in RR are
believed to offer a more powerful effect (Pangnangrong et al., 2011).
However, in this study, when adding in vitro digested RR alone to PC12 neuronal
cells, the results showed a toxic effect above 0.5% RR treatment (Figure 3.2). Perhaps
the lack of protective effect is due to accumulation of numerous active ingredients in RR.
After adding certain amount of RR, the increased amounts of other ingredients in addition
to the active ingredient responsible for the antioxidant activity of RR may bring higher
magnitude of interaction between various ingredients, leading to a masking effect or even
toxic effect (Pannangrong et al., 2011). It is also possible that high levels of RR are toxic
to cell metabolic pathways.
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A study done by Fortalezas et al. aimed to look at the antioxidant properties and
neuro-protective capacity of strawberry tree fruit. However, when raspberries were used
as control, it was found that although strawberry tree fruit has similar levels of
polyphenols as raspberries, and higher amount of antioxidants, the strawberries did not
show more neuro-protective effects. On contrary, when used in a neurodegeneration cell
model, raspberries increased neuroblastoma survival by 36.6%. The study concluded
raspberries have promising neuro-protective effects, and this protection is not all due to
antioxidant activity (Fortalezas et al., 2010). This conclusion reinforced the theory that
multiple mechanisms work together additively or synergistically to produce the neuroprotective effects of raspberries (2010).
A possible mechanism is the enhancement of neuronal interaction via increases in
neuronal signaling and decreases in stress signals induced by oxidative/inflammatory
stressors (E.g. NFκB, TNFα). Findings from Williams et al. (2008) suggested berries
can improve the performance of aged rats in memory tasks by activation of CREB and
increase of BDNF in the hippocampus. These changes correlate with increased cell
signaling related kinase, leading to the building up of extra cell signaling. In addition,
reports have shown berry supplementation decreased NFκB and TNFα expression in the
hippocampus of rats fed with kainic acid, an excitotoxin that produces neuronal lesions
and induces inflammatory response (Goyarzu et al., 2004; Shukitt-Hale et al., 2008).
Anthocyanins in raspberries have been shown to reduce the level of inflammatory
mediators in several inflammatory disease models (Rossi et al., 2003; Tsuda, Horio, &
Osawa, 2002).
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Anthocyanins in raspberries have been suggested to inhibit apoptotic pathways in
neurons. Proteins phospho-c-Jun N-terminal kinase (p-JNK) and p53 are important
mediators in various signaling pathways involved in apoptotic neuronal cell death
(Harris, Deshmukh, Tsui-Pierchala, Maroney, & Johnson, 2002; Li, Chopp, Power, &
Jiang, 1997; Irving and Bamford, 2002; Park et al., 2000; Renolleau, Benjelloun, BenAri, & Charriaut-Marlangue, 1997; Tournier et al., 2000). Shin et al. (2006)
demonstrated that anthocyanin suppressed the activation of JNK and up-regulation of
p53, and reduced JNK and p53 positive cells in brain.
Finally, berries have been shown to have geno-protective and behavioral-protective
effects by Barros et al. who gave a 30-day administration of a lyophilized extract of
vaccininium ashei berries to Swiss mice to determine the berries’ effects on DNA
damage in the hippocampus and cerebral cortex as well as cognitive performance. The
extract reduced DNA damage induced by H2O2 treatments on brain tissue and
significantly enhanced long-term memory in mice (Barros et al., 2006).
These discussed mechanisms responsible for neuro-protective effects of berries are
also the main mechanisms underlying neurotoxicity caused by DOX and cognitive
decline in cancer patients undergoing chemotherapy. This reinforced results from this
dissertation study that RR counteracts neurotoxicity caused by DOX chemotherapy.
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4.3

Interpersonal Metabolic Differences Account for Variability of Protective

Effects of Red Raspberry in Vivo
In vitro research of RR offers preliminary information that RR can counteract the
neurotoxicity caused by DOX chemotherapy, suggesting a potential for use as an
intervention for “chemobrain” in clinical practice. Of concern is the fact that molecules
reaching human circulation for distribution into tissues are different from the compounds
originally present in foods (Koli et al., 2010). Bioactivity and pharmacokinetic properties
including absorption, distribution, metabolism, and excretion of RR should play a major
role in its preventive or therapeutic application (Paredes-López et al., 2010).
Bioactivity level is determined if the concentration of a specific component reaches
a physiologically significant level at its target sites (Seeram, 2008). Pharmacokinetic
properties determine the bioavailability of certain compounds in berries, affected by the
chemical structures of the compounds and routes of metabolism (Paredes-López et al.,
2010). The in vitro digested RR used in the in vitro portion of this present study looked
at the effects of RR on neurotoxicity caused by DOX. However, this digestion process
only mimics what is happening in the stomach using pepsin and pancreatic bile salts. As
shown in Figure 4.6, metabolism of the compounds in berries not only happens in the
stomach, but also takes place as the compounds circulate and/or move through the liver,
colon and small intestines. Research indicates a majority of berry compounds are
actually metabolized and absorbed in the liver by cytochrome P450 enzymes and in the
colon by microflora (Koli et al., 2010; Manach, Scalbert, Morand, Remesy & Jimenez,
2004). To better mimic human metabolism, this study used plasma from healthy
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participants who ingested RR twice a day for over 3.5 days to look at its effects on DOX
treated PC12 neuronal cells (See Appendix C for IRB approval).
Moreover, neglecting genetic factors, the blood-brain barrier selectively allows
certain chemicals in the blood to enter the brain, so metabolized products of drugs or
foods circulated in blood account for major effect on neronal functions in brain (Dawood
& Leyland-Jones, 2009). Human plasma contains most of these metabolized products
that can be used to treat neuronal cell lines to examine the effects of the metabolized
products of RR on neuronal functions. Use of plasma from participants who have
ingested RR for over 3.5 days can mimic the internal environment of the human body
versus the in vitro digestion of RR.
In this study, post-plasma from four out of six participants exhibited beneficial
effects on the metabolic activity of PC12 neuronal cells while the other remaining two had
negative results. While the average ratio of post-plasma for six participants was higher
than that of pre-plasma with no statistical significance, the differences between postplasma ratio and pre-plasma ratio calculated by dividing post-plasma ratio by pre-plasma
ratio for each donor are quite different (#1- #6: 1.34, 1.19, 1.12, 1.05, 0.79, 0.84)
indicating that the effect could be quite significant for a particular individual, but quite
different from one individual to another. It is common to see variability of responses with
such a small sample size. Even with large sample sizes, there can be variation in
outcomes since some people are extensive metabolizers, intermediate metabolizers, poor
metabolizers or ultrarapid metabolizers, not only for drugs but also natural foods. This
variation may be due to large interindividual variations in the plasma concentration of
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metabolized berries caused by differences in the gastrointestinal metabolic system such as
microflora, by genetic differences or any other unknown external factors (Mountzouris,
McCartney, & Gibson, 2007; Rezzi, Ramadan, Fay, & Kochhar, 2007).
Secondary products with a high level of bioavailabiliy and bioactivity that account
for the neuroprotective effects of RR are still under research. Primarily, animal studies
have been used to study bioavailability of compounds in berries. For example,
metabolism and absorption of phenolics are largely dependent on aglycone structure and
the way it binds to the sugar side chains (Hollman & Katan, 1997; Hollman et al., 1999).
Those bound to glucose, such as ellagic acid, are absorbed in upper part of the gut,
stomach or small intestine after hydrolyzation and conjugation; others, such as
chlorogenic acid, go through the colon where sugar chains are cleaved by enzymes from
microflora (Olthof, Hollman, Buijsman, van Amelsvoort, & Katan, 2003; Paredes-López
et al., 2010). Anthocyanins are generally considered to be poorly metabolized and
absorbed in humans and rats (Seeram, 2008). However, some recent research suggests
anthocyanins can be absorbed in original forms or unknown modified forms that have
been biotransformed after ingestion (McGhie & Walton, 2007). Although phenolics have
limited levels in the circulation, they may be extensively metabolized or bound to other
unknown molecules, causing difficulty in lab analysis (Seeram, 2008). All the
metabolized and absorbed products of berries may adequately accumulate at target sites
and work complementarily or synergistically to contribute to the overall effects of RR in
human body.
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4.4

Redox Status and FOS Transcription
Many studies have linked epigenetic mechanisms to neuronal/cognitive function

postulating that transient reprogramming of epigenetic codes such as DNA methylation
and histone modifications is required for some basic neuronal/cognitive functions such as
neurite growth, or memory formation (Feng et al., 2010;Levenson et al., 2006; Miller &
Sweatt, 2007; Lubin et al., 2008; Korzus, 2010; Korzus et al., 2004; Miller et al., 2008).
As shown in Figure 1.1, folate acid in RR is a key factor in the epigenetic methylation
pathway (Abbott, Ronnback, Hansson, 2006; Liu, Wylie, & Tollefsbol, 2003; Niculescu
& Zeisel, 2002). The intake of folate acid influences the global availability of methyl
groups for DNA or histone methylation. The methylation of DNA or histone can recruit
different chromatin remodeling complexes to promote compacting or openning of
chromatin in order to regulate gene transcription. The activation and silencing of some
genes important in brain neuron function can lead to changes in cognitive function
(Miller & Sweatt, 2007). Therefore, the original hypothesis of this study was that RR
treated PC12 neuronal cells had different DNA methylation patterns compared to control
cells or DOX treated cells. However, the study revealed different outcomes.
Table 4.1 shows genes originally planned for screening during the study and the
functions of their gene products. Only the methylated- and unmethylated-specific
primers designed for EGR1, BDNF and FOS genes resulted in products in PCR. Tested
primers are listed in Table 2.1.
Immediate early genes are a set of first genes expressed in response to cellular
stimulation. They are usually induced within minutes of stimulation and are transiently
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expressed (Tischmeyer & Grimm, 1999; O’Donnell, Odrowaz, & Sharrocks, 2012).
After stimulation, their expression enter an activated phase, then go back to a repressed
phase and stay at a more than basal level of expression (O’Donnell et al., 2012). The
EGR1 gene, also known as Zif 268, Krox-24, NGFI-A, or Zenk, is one of these immediate
early genes that encode transcriptional factors to interact with the promotor or regulatory
region of a set of effector genes (Bozon et al., 2002). It belongs to a multigene family
encoding closely related transcriptional factors EGR-2 (Krox-20), EGR-3, and EGR-4
(NGFI-C). These transcriptional factors are required for cell growth, differentiation and
apoptosis (Gashler & Sukhatme, 1995; Bozon et al., 2002; Jones et al., 2001). Among
these genes, EGR1 has been shown to be necessary for the formation of long-term
memory (Jones et al., 2001; Bozon et al., 2002).
This study looked at the methylation pattern of the EGR1 gene in the control, DOX
treated, RR treated and combination treated PC12 neuronal cells by MSP. Results
indicated an unmethylated EGR1 gene for all samples. That is, there is no difference as
regard to whether the gene is methylated or unmethylated among the control and the
treated PC12 neuronal cells. Unmethylation of genes usually, although not necessarily,
leads to gene expression and gene products. High density of methylation usually leads to
reduction of transcriptional activity (Ebinger, Senf, Wachowski, & Scheurlen, 2004).
This result can be explained by the finding that the EGR1 gene encodes the protein that is
expressed responding to NGF treatment in rat PC12 cells (Lemaire, Revelant, Bravo, &
Charnay, 1988). Since all the samples were treated by NGF in order to induce
differentiation of PC12 into neuronal cells, the unmethylated EGR1 gene and its
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expression is essential for its response to growth factor treatment. In addition, this result
also indicates DOX and/or RR treatment(s) did not change DNA methylation pattern of
EGR1 gene in PC12 neuronal cells.
BDNF gene is a member of the neurotrophin family, encodes a secreted protein that
plays an important role in neuronal survival, differentiation, growth and morphology
maintenance (Aid et al., 2007; Bibel & Barde, 2000; Binder & Scharfman, 2004; Chao,
Rajagopal, & Lee, 2006). It is also implicated essential in memory and learning (Hall,
Thomas, & Everitt, 2000; Linnarsson, Bjorklund, & Ernfors, 1997; Lubin et al., 2008;)
The BDNF gene is composed of nine 5’ noncoding exons and one 3’ coding exon. Each
of these exons has a promoter region that regulates its transcription. The combinations of
different noncoding exons and the common coding exon dictates different mRNA
isoforms, which are stimulated by cellular stimuli and in turn regulate subsequent
activities of the transcripts (Aranda-Abreu, Hernandez, Soto, & Manzo, 2005;
Blichenberg et al., 1999; Lauterborn et al., 1996; Lubin et al., 2008; Nanda & Mack,
1998; Pal et al., 2003).
The present study looked at the methylation pattern of BDNF gene of the control,
DOX treated, RR treated and combination treated PC12 neuronal cells by MSP. The
methylated-specific and unmethylated-specific primers were designed to detect the whole
BDNF gene with nine 5’ noncoding exons and one 3’ coding exon. There is no
difference whether the gene is methylated or unmethylated for BDNF among the control
and groups of treated PC12 neuronal cells. All the samples showed both strong
methylation and weak unmethylation signals for BDNF gene (Table 3.4), possibly due to
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the heterogeneous maturation stages of the NGF induced PC12 neuronal cells. The
differentiation of PC12 cells into neuron-like cells are characterized by both the extension
of neurites and the cessation of proliferation (Hahn, Jones, & Meyer, 2009). In this study,
the differentiation of PC12 cells was determined by visual examination of the neurite
growth. Theoretically after six days of induction with NGF, PC12 cells should be
differentiated into neuron-like cells (Adler et al., 2006). However, although most of the
cells developed neurites by the end of treatments, it was not guaranteed that all the cells
were differentiated. According to the cell cycle study of PC12 cells, the cells can be
arrested in both G1 and G2/M phases and neurite growth can take place before cell cycle
arrest (Hanh, Jones, & Meyer, 2009). That is, cells that developed neurites may not have
been arrested and differentiated, thus contributing to the heterogeneity of the cell
population.
FOS gene, also belongs to immediate gene family and functions as a transcriptional
factor to mediate acute extracellular signals/treatments and long-term changes in neuronal
cells (Chen, Xie, Stevenson, Auron, & Calderwood, 1997; Kovacs, 1998; Hiroi et al.,
1997). C-Fos, FosB, Fra-1 and Fra-2 are the major protein members of Fos family that
are encoded by genes containing four exons and three introns (Cohen & Curran, 1988;
Greenberg & Ziff, 1984; Nishina, Sato, Suzuki, & Iba, 1990; van Straaten, Muller,
Curran, van Beveren, & Verma, 1983; Zerial et al., 1989). Fos proteins dimerize with
members in Jun family including c-Jun, JunB and JunD to form a transcriptional factor
named activator protein-1 (AP-1) (Kovacs, 1998; Hughes & Dragunow, 1995).
Heterodimer AP-1 complexes recognize DNA sequence TGACTCA in the regulatory
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regions of targeted genes to promote or suppress gene expression (Rauscher et al., 1988).
The regulation of these subsequent genes should be coordinated by several classes of
regulatory proteins, never a task completed by a single class of proteins (Kovacs, 1998).
This research looked at the methylation pattern of FOS gene for the control, DOX
treated, RR treated and combination treated PC12 neuronal cells by MSP. Results
indicate DOX treated and combination treated PC12 neuronal cells have a different
methylation pattern compared to control and RR treated cells. Specifically, all the
samples showed unmethylation signals while only DOX treated and combination treated
PC12 neuronal cells showed methylation signals for FOS gene.
All the samples in this research showed unmethylation signals for FOS gene, which
facilitates gene transcription. This finding reinforced the results of previous studies
concluding NGF injections or more generally growth factors can induce transcription and
translation of immediate-early genes including FOS gene (Sharp, Gonzalez, Hisanaga,
Mobley, & Sagar, 1989; Rivera & Greenberg, 1990). It was reported that in the case of
FOS gene, the serum response element, a dyad symmetrical sequence located upstream of
the gene, responds to the binding of a complex of proteins that are stimulated by growth
factor signals, in order to activate and repress transcription of FOS (Rivera & Greenberg,
1990). However, it is probable this is not the single mechanism that facilitates FOS
expression. From the results of the present study, unmethylation of FOS may also play a
role in the promoting of gene expression in responds to growth factors.
Only DOX treated and combination treated PC12 neuronal cells showed
methylation signals for FOS gene in this study. As discussed in previous sections, DOX
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treatment leads to oxidative stress in neuronal cells. Activator protein-1, heterodimerized
by c-Fos and c-Jun proteins, is one of the well characterized redox (reduction-oxidation)
sensitive transcriptional factors (Kunsch & Medford, 1999; Winyard & Blake, 1997; Sun
& Oberley, 1996). Redox sensitive trasncriptional factors are modulated by redox
sensitive signaling pathways by two levels of mechanisms: 1) transcriptional level and 2)
post-translational level. They respond to intracelluar reduction-oxidation status and
target subsequent genes to regulate the magnitude and specificity of their expressions
(Kunsch & Medford, 1999). Theoretically, as the precusor of AP-1 protein, c-Fos
transcription or translation is possibly regulated first in order to modulate the presence or
magnitude of AP-1 protein (Sun & Oberley, 1996). In fact, some researchers have
reported that c-Fos and c-Jun expression is indeed also regulated by celluar
environmental redox status (Rao, Lassegue, Griendling, & Alexander, 1993), and the
activity of AP-1 protein relies on de novo synthesis of c-Fos and c-Jun mRNAs ( Meyer
et al., 1994). There is research indicating reductants activate AP-1 activity while
oxidants inhibit AP-1 activity (Sun & Oberley, 1996). However, there is also research
indicating both oxidant H2O2 and antioxidant PDTC induce AP-1 activation, but this
requires post-translational modification of tyrosine and serine, and mediation of Jun
protein phosphorylation (Barchowsky, Munro, Morana, Vincenti, & Treadwell, 1995;
Meyer et al., 1994). These paradoxical results suggest the complexity of regulation
networks in the modulation of redox status (Kunsch & Medford, 1999). DNA
methylation is one of the mechanisms that regulate transcription of FOS gene, which,
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from the results of the present study, may also play a role in the response to oxidative
stress caused by DOX in PC12 neuronal cells.
In addition, DOX treated cells and DOX plus digested red raspberry treated cells
both showed the same pattern of unmethylation and methylation signals for FOS gene in
this study. This indicates digested red raspberry did not counteract methylation changes
induced by DOX. As previously discussed (Section 4.2), the neuro-protective effects
against DOX exhibited by red raspberry are probably due to the antioxidant, antiinflammatory, anti-apoptosis, genoprotective effect of phenolic compounds in berries.
This research screened sample sets harvested from seven different days. Each
sample set includes the control PC12 neuronal cells, DOX treated, RR treated, and
combination of DOX and RR treated PC12 neuronal cells. Although majority of the
sample sets showed methylation signals for DOX treated and combination treated PC12
neuronal cells, there were exceptions that did not show any methylation signals (only
showed unmethylation signals). This is probably also due to the variability of maturation
stages of PC12 samples from different days, the transient nature of immediate early gene
induction that is not easily captured, and the sensitive limit of MSP (Tischmeyer &
Grimm, 1999; Hughes & Dragunow, 1995; Herrera & Robertson, 1996).
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CHAPTER FIVE CONCLUSIONS & FUTURE WORK
This chapter includes conclusions and future work of this dissertation. The section
of conclusions summarizes the results and accomplishments of this dissertation research.
The section of future work focuses on identifying areas of research that this dissertation
can possibly lead to.

5.1

Conclusions
This dissertation is the first contribution to show the effects of in vitro digested and

in vivo human metabolized RR on DOX chemotherapy induced neurotoxicity in NGF
induced PC12 neuronal cells, and to suggest epigenetic DNA methylation changes are
associated with this process. A better understanding of neurotoxicity of DOX and
neuroprotection of RR at the cell and epigenetic level has been initiated. Human plasma
containing the in vivo metabolized products of RR was used in this work. This novel
methodology mimicks the internal environment in the human body showing metabolized
RR has a potential to protect neurons. This interdiciplinary study utilizing knowledge
from cell biology, molecular genetics, epigenetics, medicine, nursing, and nutrition, is a
representation of bench research in the discipline of healthcare genetics, with the
potential for translation into the clinical arena. Major conclusions of this dissertation are
summarized in the following paragraphs.
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5.1.1 Effects of Doxorubicin on Metabolic Activity of PC12 Neuronal Cells
Neurotoxicity associated with chemotherapy has been well documented in both the
laboratory and clinical settings (Ahles et al., 2002; Brezden et al., 2000; Downie et al.,
2006; Jansen et al., 2010; Schagen et al., 1999; Shilling et al., 2005; Wefel et al., 2004).
This study specifically looked at effects of DOX chemotherapy on metabolic activity of
NGF induced PC12 neuronal cells. It was found that: 1) as minute amount as 0.001µM
of DOX reduced the metabolic activity of NGF induced PC12 neuronal cells; 2) with the
increase of concentration of DOX, the metabolic acitivity of NGF induced PC12 neuronal
cells decreased; and 3) when the concentration of DOX was greater than 1µM, metabolic
activity of NGF induced PC12 neuronal cells decreased abruptly. These results indicate
as small amount as 0.001µM of DOX can potentially cause neurotoxicity. The
mechanisms responsible for the neurotoxic effects of DOX can include direct neuronal
toxicity, secondary neurotoxic metabolites such as inflammatory cytokines that can pass
the blood-brain barrier, free radical mediated oxidative stress and DNA damage. The
mechanism responsible for cell death may have shifted from apoptosis to necrosis around
1µM of DOX.

5.1.2 Effects of in Vitro Digested Red Raspberry on Doxorubicin Treated PC12
Neuronal Cells
This study looked at effects of in vitro digested RR on metabolic activity of PC12
neuronal cells by MTS assay. It was found that: 1) in vitro digested RR did not
statistically affect the metabolic activity of PC12 neuronal cells, although there was a
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trend of increased metabolic activity for 0.0625% to 0.5% digested raspberry treated cells
and decreased metabolic activity for over 1% digested raspberry treated cells; 2) the
metabolic activity of cells treated with a combination of 0.1% digested RR and 1µM or
0.1µM of DOX was higher than that of cells treated with DOX alone; 3) with increased
concentrations of DOX, the differences between metabolic activities of cells treated with
and without digested raspberry decreased; 4) the cells treated with digested RR had more
neurite connections compared to control cells treated with DMSO; and 5) the cells treated
with digested RR plus DOX had more neurite connections compared to cells treated with
DOX alone. These results extend the findings showing that berries display neuroprotective effects in various in vitro and in vivo models of toxicity (Fortalezas et al.,
2010; Joseph et al., 2009;Kang et al., 2006; Shin et al., 2006; Pannangrong et al., 2011;
Ramiro-Puig et al., 2009). The mechanisms responsible for the neuro-protective effects
of RR against DOX chemotherapy likely include the high antioxidant activity,
involvement in anti-inflammatory/anti-stress signaling pathways, inhibition of apoptotic
pathways, and genoprotective effect of phenolic compounds in berries (Barros et al.,
2006; Fortalezas et al., 2010; Joseph et al., 2009; Kang et al., 2006; Pangnangrong et al.,
2011; Shin et al., 2006). The high levels of total phenolic compounds especially
anthocyanins, ellagic acid, flavonols, and stilbenes in RR may contribute to these
working mechanisms.
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5.1.3 Effects of Human Plasma Collected Prior to and After Red Raspberry
Consumption on Doxorubicin Treated PC12 Neuronal Cells
Most traditional neurobiological research uses food extracts to treat neuronal cell
lines to determine the neurotoxicity or neuro-protective effects of the extracts. However,
the extracts used were not metabolized in vivo. This study addresses this methodological
limitation by using human plasma that contains the in vivo primary and secondary
metabolic products of RR, mimicking the internal environment in the human body rather
than using in vitro digested RR alone. Post-plasma of participants #1-#4 showed a neuroprotective effect against DOX chemotherapy, while post-plasma of participants #5 & #6
did not show such effect. The protective index of post-plasma for six participants is
higher than that of pre-plasma with no statistical significance. These individual
variations could be caused by any difference in the metabolic system such as microflora,
by genetic differences or other external factors such as diet (Mountzouris et al., 2007;
Rezzi et al., 2007). The metabolized products that have a high level of bioavailabiliy and
bioactivity and account for the neuroprotective effects of RR are not clear. Phenolics
such as Anthocyanins are candidates under research.

5.1.4 Effects of Doxorubicin, in Vitro Digested Red Raspberry, and Combination
on DNA Methylation of PC12 Neuronal Cells
Many studies have linked epigenetic mechanisms to neuronal/cognitive functions
postulating that transient reprogramming of epigenetic codes such as DNA methylation
and histone modifications is required for some basic neuronal/cognitive functions such as
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neuron growth or memory formation (Feng et al., 2010; Levenson et al., 2006; Miller &
Sweatt, 2007; Lubin et al., 2008; Korzus, 2010; Korzus et al., 2004; Miller et al., 2008).
This study looked at the methylation pattern of EGR1 gene, BDNF gene and FOS gene of
the control, DOX treated, RR treated and combination treated PC12 neuronal cells by
MSP. Results showed that: 1) the methylation pattern of EGR1 and BDNF stays the same
for DNA of the control, DOX treated, digested RR treated, and combination treated PC12
neuronal cells; and 2) majority of the screened sample sets showed a difference in the
methylation pattern of FOS for DNA from both DOX treated and combination treated
PC12 neuronal cells compared to control and RR treated cells. Unmethylation of genes
usually, although not necessarily, leads to gene expression and gene products. High
density of methylation usually leads to reduction of transcriptional activity (Ebinger et
al., 2004).

5.2

Future Work
While this dissertation reveals some interesting phenomena in neuronal function and

epigenetics in vitro, there are still many questions to investigate. To enhance
understanding of the neuro-protective effects of RR, the underlying mechanisms, and
determine its clinical application, the recommended future studies are summarized as
follows:
1) A primary neuronal cell line is needed in future research to replace PC12 neuronal
cell line. PC12 neuronal cell line is derived from a pheochromocytoma of the rat
adrenal medulla. Embryologically, adrenal medulla cells and postganglionic
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neurons are developed from the same progenitors (Greene, 1982). When grown in
vitro, in the presence of NGF, the adrenal cells exhibit neuronal behavior. The
PC12 cell line is easier to manipulate in the lab than primary neuronal cell lines
and is considered a standard cell model for neuron study (Alder et al., 2006).
However, NGF induced PC12 neuronal cells only develop neurites but not
synapses. From this point of view, a primary neuron cell line should be a good
choice to further this study. Comparison of results from the primary cell line and
PC12 cell line should offer more information on the differences between cell lines
and provide basis for future similar neurotoxicity research.
2) Neurite outgrowth is a fundamental process in neuronal development and a good
indicator of neuron function. It is expected that the introduction of more accurate
parameters for neurite growth, such as total length, maximum length, root count,
extremities count, node points and segment count etc., should help improve the
prediction accuracy. Also, advanced analysis platforms and software with an
algorithm that analyzes fluorescent images is expected to better characterize fine
and complex neuronal structures in further study.
3) Some interesting observations of effects of RR on DOX treated PC12 neuronal
cells have been observed, but further work is needed to enhance understanding of
these phenomena, especially from cellular and molecular perspective. The
components in RR that work as neuro-protective contents after human
metabolism, and the pathways through which these components work remain to
be revealed in future research.
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4) Interesting results in DNA methylation changes induced by DOX chemotherapy
have been observed by methylation specific PCR. Further experimental and/or
analytical research is expected to better elucidate the process. The future work
may focus on looking at DNA methylation of other genes, quantifying the amount
of DNA methylation, and investigating other epigenetic mechanisms especially
histone acetylation. Synchronizing cells before measurement should help to
improve the accuracy of results.
5) The goal of studying the effect of DOX on neuronal cells is to prevent
neurotoxicity of DOX. Understanding the underlying biological pathways that
account for the neuronal toxic effects of DOX should help design right-to-target
preventions in order to achieve this goal. This dissertation suggests DOX can
induce apoptosis or necrosis, or both at different ranges of concentrations,
indicating there are possibly more than one pathway involved in neurotoxicity of
DOX. Fully understanding how chemical messengers deregulated in cancer
patients, such as inflammatory cytokines and estrogens, are involved in these
pathways may help maximize anti-cancer effects and minimize side effects of
DOX administration. In addition, this dissertation showed DNA methylation
status of DOX treated PC12 neuronal cells was different from the control cells.
Therefore, further study can also focus on exploring how DOX initiates the DNA
methylation changes and how these changes are involved in cell death pathways.
6) Promising results have been observed in this study in vitro and in vivo. In order to
achieve the ultimate goal of this study to use RR as a natural intervention to
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prevent cognitive impairments of cancer patients receiving DOX chemotherapy, a
preliminary clinical research needs to be conducted. Key research activities
should include evaluating cognitive performance of cancer patients receiving
DOX chemotherapy, evaluating the effect of natural RR on cognitive performance
of cancer patients receiving DOX chemotherapy, and exploring the epigenetic
changes and other biological pathways associated with this process. The
investigation of underlying pathways can be done using neuronal cell lines treated
with blood plasma that contains DOX chemotherapy in vivo metabolized by
cancer patients. The changes of biological parameters in blood plasma and plasma
treated neurons can be correlated with changes of cognitive performance for each
participant. Appendix A describes a possible preliminary clinical research plan. In
the future study, it is important to explore the potential benefits as well as possible
side/toxic effects in order to throughly understand how an natural intervention,
such as RR intake for prevention of chemotherapy induced cognitive
impairments, can be personalized.
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APPENDICES
Appendix A Plan for preliminary clinical research
(i)

Participant plan and description
By power analysis of G*Power 3.0.10, group sample size of N = 25 is required to

provide 80% power (p < 0.05) to detect a mean difference of 0.25 (σ = 0.50) with effect
size 0.6 for paired t-test. Group sample size of N = 26 is required to provide 80% power
(p < 0.05) to detect a mean difference of 0.25 (σ = 0.50) with effect size 0.8 for unpaired
t-test. An additional 20% will be added to account for attrition. Therefore, the planned
sample size is ≥30 participants. However, for a preliminary clinical research, 10-20 per
group should be acceptable.
Patients will be recruited from a hospital setting. Women diagnosed with Stage I-II
breast cancer will be invited to participate by a designated study researcher if inclusion
and exclusion criteria are met. After the women agree to participate, an investigator will
contact them, explain the study procedures and obtain written informed consent.

Inclusion Criteria
•Post-menopausal female
•ER+/PR+ and HER2/neu •Stage I-II breast cancer
•Chemotherapy
•Consensus Lumpectomy status
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Exclusion Criteria
•History of head injury
•Evidence of delirium, dementia, aphasia
•A previous diagnosed psychiatric illness
•Alcohol or drug abuse
•Central nervous disease
•A previous malignancy
•Previous chemotherapy
•Current cortisol medication
•Current medication involving methyl group
•History of allergy to RR, tomato-based foods, jams, licorice, thyme, dill and chestnuts.

(ii)

Overview of methods/implementation (i.e., procedures for data collection,

interventions, measures)
Participants will be randomly assigned to two groups: control group and treatment
group.
1) Participants in control group will be given a battery of cognitive tests described
later, and a 4*7ml blood draw pre-chemotherapy treatment at week 1, the end of the first
cycle of chemotherapy at week 4, the end of third cycle at week 10, 4 weeks posttreatment at week 23. (Figure Appendix A.1).
2) Participants in treatment group will be given an additional cognitive test and
blood draw pre-raspberry treatment at week 0. In addition, they will be asked to eat two
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cups of freeze-dried RR per day for 3.5 days before chemotherapy, with half being
ingested in the morning and half in the evening. On the fourth day, participants will be
asked to eat one cup of berries in the morning, (for a total of 3.5 days of berry intake) and
return to clinic 2-4 hours after the last berry consumption to have their cognitive test,
blood draw and chemotherapy (Figure Appendix A.1).
After each blood draw, the plasma will be separated from the blood and frozen for
later analysis. Levels of estrodiol, progesterone, cortisol, and cytokines IL-1β, IL-6 and
TNF-α in blood plasma will be measured. The plasma will be also added to the
experimental medium to maintain the PC12 neuronal cell line for neuronal metabolic
activity measurements.
The changes of biological parameters in blood plasma and plasma treated neurons
will be correlated with changes of cognitive performance for each participant.
Cognitive tests include the stroop test, the memory span test, and the levels of
processing test. The Stroop Test is a valid and reliable test to measure the executive
function and inhibitory control of participants. The test requires participants to name the
ink color that the words are printed in, which may be the same or different from the color
that the words (such as yellow, blue, black) indicate. The score for Stroop Test can be
adjusted by participant’s age and educational level, with higher scores indicating better
cognitive function.
The Memory Span test is a robust test to measure working memory of participants.
One each trial, you see a list of items presented one at a time in a random order and are
asked to recall the items in the same order in which they are presented. If you get a list
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correct, the list length increases by 1 for that type of material. If you get a list incorrect,
the list length decreases by 1. The independence variable is the type of material you were
asked to recall: digits, letters that sound dissimilar, letters that sound similar, short words,
and long words. The dependent variable is the list length of the last list you correctly
recalled.
Levels of Processing test is a reliable and robust test to measure semantic memory
and episodic memory of participants. There are two parts to this experiment. In Phase I,
you are given a word and a judgment task. In Phase II, you see a series of words, half of
which have been shown in Phase I. For each word, you were asked to indicate if it had
been shown in Phase I. The logic of the test is that Phase I tests the words in your
semantic memory, and if you can remember which words were presented in the first test
section, that means you can remember what happened to you in the past, thus you can
retrieval from your episodic memory.
Participants will be given these cognitive tests pre-raspberry treatment at week 0 (if
they are in treatment group), pre-chemotherapy at week 1, the end of the first cycle of
chemotherapy at week 4, the end of third cycle at week 10, 4 weeks post-treatment at
week 23. (Figure Appendix A.1).
4*7ml vials of whole blood will be collected for each participant using green top
tubes from BD (Franklin Lakes, NJ) and transported for centrifuging within 4 hours.
Tubes containing heparin will be inverted 8 to 10 times after collection to ensure
thorough mixing of the lithium heparin with the blood and, therefore, complete
anticoagulation of the sample.
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The tubes with the separation gels will be centrifuged for 10 mins at 1000 - 1300
RCF (g-force) in swinging bucket rotor to separate into plasma and red blood cell layers.
The tubes will be removed from the centrifuge, and opened in a clean and safe
environment to access the plasma located at the top of the specimen. Using a sterile
transfer pipet or a 1000 µl pipettor, the plasma will be carefully transferred into
appropriately labeled amber screw-cap microcentrifuge tubes. As soon as possible, the
collected plasma will be placed and stored at -80°.
It is important to minimize the contact of plasma with blood cells, plasma left in
room temperature (should be -80°C) and freeze thaw cycle (should be ≤ 2) during this
process. Blood and plasma will be transported in an approved biohazard container.
Labeled frozen plasma samples will be evaluated for levels of estradiol, cortisol and
progesterone and cytokines IL-1β, IL-6 and TNF-α.

(iii)

Statistical analyses if applicable and/or methods of evaluation of the goals,

objectives, and outcomes of the proposed project
Statistical analyses will be performed using the Statistical Package for the Social
Sciences (SPSS/PASW) Version 18.0. Descriptive statistics and frequency distributions
will be generated for demographic, disease and treatment characteristics. T-test will be
used to test the differences of biological indicators between neurons treated with plasma
from control group and treatment group. The significance levels will be set at .05 for all
analyses. Linear Regression will be used to evaluate the trajectory of cognitive function
and biological indicators over time. For subsequent analyses, ANOVA will be used to
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look at the correlation between neuronal function changes measured in vitro and
cognitive performance changes of breast cancer patients in clinical setting.

(iv)

Expected outcomes
It is expected that the in vitro digested RR can protect PC12 neuronal cells from

detrimental alterations caused by in vivo metabolized DOX chemotherapy. It is also
expected that neuron metabolic activity, oxidative stress, cytokine levels, estrogen &
cortisol hormone levels, and epigenetic DNA methylation are associated with this
process.

(v)

Potential problems and alternative strategies if something does not go as

planned
If participant recruitment takes longer than expected, or participant number cannot
reach the number originally planned, alternative strategies may include selecting multiple
research sites, loosening inclusion criteria, and recruiting patients with other cancers
besides breast cancer who are being treated with DOX chemotherapy.

72

73

Appendix B Lab Protocols

Collagen Coating Protocol:
1.

Prepare 0.1N acetic acid (AA) by adding 1.15ml of 17.4N AA to 198.85ml

Double Distilled (DD) water.
2.

Add 3.2mg collagen to 3.2ml of 0.1N AA to prepare 1mg/ml solution. Dissolve

by gentle shaking.
3.

Add 150µl of 1 mg/ml collagen to 2850 µl 1*PBS (sterile) to prepare .05mg/ml

solution.
4.

Add 33 µl of solution from step 3 to each well (well size: 0.28cm2, 0.2 ml) if

using plates.
5.

Add 450 µl of solution from step 3 to each flask if using flasks.

6.

Refrigerate at 4 °C for no longer than 3 weeks’ storage.

Red Raspberry Digestion Protocol:
1.

Add 10mL of RR to a 50mL conical tube

2.

Adjust pH to 2.8 with 6N HCl

3.

Add 0.5 ml of Pepsin Suspension (4g/L pepsin in 0.1 N HCl)

4.

Incubate at 37°C with shaking for 2 hrs

5.

Adjust pH to 5.7 with 1 N NaOH

6.

Add 2.5 ml of Pancreatic Bile Salts [0.2g Pancreatin and 1.2 g Bile Salts in 100

ml of 0.1 M NaHCO3 (sodium bicarbonate)] solution to each tube
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7.

Incubate at 37°C with shaking for 2 hrs

8.

Centrifuge tubes for 10 min at 4,500 rpm (~ 3500 g)

9.

Transfer supernatant to 15 mL conical and store at 4°C refrigerator

10.

Filter sterilize approximately 3 mL of supernatant into sterile culture tube by

passage through 2µ syringe filter
11.

Use for treatment of cells or store at 4°C refrigerator
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Table 2.1
Designed primers for methylation specific PCR
Gene

Primers

Product size

LM: AGATTTTTGAAATAGAGGTCGATTC
RM: AACTAAAACAAAAACCGATCTTACG

M: 129 bp

LU: TAGATTTTTGAAATAGAGGTTGATTTG

U: 131 bp

EGR1/Zif 268
RU: AAACTAAAACAAAAACCAATCTTACAAC

LM: TTTTAGTTTTTTTTGGTAGAGACGA
RM: CACATTACTTATAAAACCTTTCGAA

M: 206 bp

LU: TTTTAGTTTTTTTTGGTAGAGATGA

U: 206 bp

GR/NR3C1
RU: CACATTACTTATAAAACCTTTCAAA

LM: CGGAAAGTATTAGAGGTAGGGTAGC
RM: TATATACAACTAAATCCGCCCTACG

M: 147 bp

LU: TTGGAAAGTATTAGAGGTAGGGTAGTG

U: 146 bp

BDNF
RU: TATACAACTAAATCCACCCTACAAA

LM: TAATTGAGAAGATTGGATAGAGTCG
RM: CGCTACTACAACGAAAAAATAACG

M: 190 bp

LU: AGTAATTGAGAAGATTGGATAGAGTTG

U: 192 bp

FOS
RU: CACTACTACAACAAAAAAATAACACC

LM: GTTTTTTTAGAACGGGTTTTAATTC

M: 181 bp

RM: AATACCGAATACGCAACGAC

U: 182 bp

CREB
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LU: TTTTTTAGAATGGGTTTTAATTTGT
RU: CCCAATACCAAATACACAACAAC

LM: TTTCGGATTTATTTTTACGATTATC
RM: AAACTCAAAACTATCCCTTCGAC

M: 223 bp

LU: TTGGATTTATTTTTATGATTATTGA

U: 222 bp

TNF
RU: CAAACTCAAAACTATCCCTTCAAC

LM: AATTGGTTTTGGTGAAAAATTATAC
RM: AAAAAATAAAAACTAAATAATAAATATCGA

M: 262 bp

LU: TTGGTTTTGGTGAAAAATTATATGA

U: 259 bp

Tp53
RU: TAAAAAATAAAAACTAAATAATAAATATCA
Notes: These primers were used in MSP, and the bolded primers were the primers worked in
MSP. L: Left; R: Right; M: Methylated; U: Unmethylated; EGR1: Early Growth Response 1; GR:
Glucocorticoid Receptor; BDNF: Brain-derived Neurotrophic Factor; CREB: cAMP response
element-binding; TNF: Tumor necrosis factor.
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Table 3.1
Data for metabolic activity of doxorubicin treated PC12 neuronal cells
Average
Standard
Metabolic

p-value
Error

Activity
DMSO control

1

0

DOX 0.001µM

0.869

0.035

0.032

DOX 0.01µM

0.715

0.068

0.025

0.036

DOX 0.1µM

0.595

0.117

0.041

0.045

0.205

DOX 1µM

0.537

0.103

0.020

0.017

0.035

0.161

DOX 10µM

0.357

0.071

0.003

0.001

0.0004

0.026

0.0168

Notes: The metabolic activities of PC12 neuronal cells treated with various concentrations of
DOX were all statistically different from the DMSO control. The results indicate minute amounts
of DOX reduced the metabolic activity of PC12 neuronal cells, exibiting neurotoxicity. Data
were compared by two-tail Student t-test with p < 0.05 considered statistically significant.
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Table 3.2
Data for metabolic activity of in vitro digested red raspberry treated PC12 neuronal cells
Average Metabolic
Standard Error

p-value

Activity
Water control

1

0

1.136

0.079

RR 0.125%

1.138

0.0677

0.097

RR 0.25%

1.068

0.0811

0.440

RR 0.5%

1.041

0.0543

0.483

RR 1%

0.819

0.0893

0.098

RR 0.0625%

0.146

Notes: Compared to control, metabolic activity of 0.0625% to 0.5% digested RR treated PC12
neuronal cells increased and metabolic activity of 1% of in vitro digested RR treated cells
decreased without statistical significance. The results indicate 0.0625% to 0.5% in vitro digested
RR have the potential to promote metabolic activity of PC12 neuronal cells. Data were compared
by two-tail Student t-test with p < 0.05 considered statistically significant.
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Table 3.3
Data for metabolic activity of doxorubicin plus in vitro digested red raspberry treated PC12
neuronal cells
RR 0%

RR 0.1%

p-value

DOX 0M

1

1.232±0.061

0.013

DOX 0.1µM

0.966±0.088

1.178±0.024

0.035

0.897±0.080

1.088±0.023

0.057

DOX 1µM

Notes: The metabolic activity of PC12 neuronal cells treated with combinations of in vitro
digested RR and DOX were higher compared to that of cells treated with DOX alone (p = 0.035
& 0.057). The results indicate in vitro digested RR counteracted the neuro-toxic effect of low
concentrations of DOX on metabolic activity of PC12 neuronal cells. Data were compared by
two-tail Student t-test with p < 0.05 considered statistically significant.
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Table 3.4
Methylation patterns of BDNF, EGR1 and FOS genes for DNA from the control and treated
PC12 neuronal cells
Primers

Control

DOX

RR

DOX + RR

EGR1_U
EGR1_M
BDNF_U
BDNF_M
FOS_U
FOS_M
Notes: The methylation patterns of EGR1 and BDNF were the same for DNA of control, DOX
treated, digested RR treated, and combination treated PC12 neuronal cells; methylation pattern of
FOS changed for DNA of DOX and combination treated PC12 neuronal cells compared to control
and in vitro digested RR treated cells.

The results indicate treatments did not change the

methylation pattern of EGR1 and BDNF genes, but changed the methylation pattern of FOS gene.
Black shade: Strong band in gel electrophoresis; Grey shade: Weak band in gel electrophoresis;
White shade: No band in gel electrophoresis; Control: DNA of control PC12 neuronal cells;
DOX: DNA of DOX treated PC12 neuronal cells; RR: DNA of in vitro digested RR treated PC12
neuronal cells; DOX+RR: DNA of PC12 neuronal cells treated with DOX plus in vitro digested
RR.
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Table 3.5
Screening of methylation pattern of FOS gene for DNA from the control and treated PC12
neuronal cells
Control
FOS_M

RR

DOX

DOX + RR

*

*

*

*

*

*

*

*

*

Feb 25th sample
Mar 4th sample
Mar 9th sample
Apr 5th sample
Apr 23rd sample
Jun 14th sample
Jun 20th sample

FOS_U

Feb 25th sample

*

*

*

*

Mar 4th sample

*

*

*

*

Mar 9th sample

*

*

*

*

Apr 5th sample

*

*

*

*

Apr 23rd sample

*

*

*

*

Jun 14th sample

*

*

*

*

Jun 20th sample

*

*

*

*

Notes: A majority of the screened sample sets showed a difference in the methylation pattern of
FOS gene for DNA from DOX treated and combination treated PC12 neuronal cells. The results
indicate DOX treatment may have induced FOS gene methylation, while in vitro digested RR did
not reverse this effect. *: Band in gel electrophoresis; M: Methylated; U: Unmethylated; Control:
DNA of control PC12 neuronal cells; DOX: DNA of DOX treated PC12 neuronal cells; RR:
DNA of in vitro digested RR treated PC12 neuronal cells; DOX+RR: DNA of PC12 neuronal
cells treated with DOX plus in vitro digested RR.
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Table 4.1
Genes and functions of gene products
Genes

EGR1/Zif 268

Functions of Gene Products
Transcriptional factor; Required for memory formation, differentiation
and mitogenesis (Bozon et al., 2002; Jones et al., 2001)
Transcriptional

GR/NR3C1

factor;

Inflammatory/Stress

response;

Cellular

proliferation & differentiation (Lu & Cidlowski, 2004; Barnes, 1998;
Sapolsky, Romero, & Munck , 2000)

BDNF

TNF
TP53
CREB

Transcriptional factor; Support the survival of existing neurons, encourage
neurite outgrowth and cell plasticity (Aid et al., 2007)
Cytokine in inflammation; Regulation of immune cells
(Pfeffer, 2003)
DNA repair and apoptosis (Bai & Zhu, 2006)
Transcriptional factor; Neuronal survival, proliferation and differentiation;
Formation of long-term memory (Lonze & Ginty, 2002)
Proto-oncogene; immediate early gene family of transcription factors;

FOS

regulates genes involved in proliferation and differentiation to defense
against invasion and cell damage; Up regulation indicates recent neuronal
activity (Hu et al., 1994; Kovács, 1998)

Notes: These genes are frequently targeted in research of cognitive functions, and were tested in
this study for changes of DNA methylation. EGR1: Early Growth Response 1; GR:
Glucocorticoid Receptor; BDNF: Brain-derived Neurotrophic Factor; CREB: cAMP response
element-binding; TNF: Tumor necrosis factor.
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Figure 1.1. Methylation pathway

Figure 1.1. A schematic diagram showing folate acid in berries is involved in DNA/histone methylation.
Adapted from “Aging, cancer and nutrition: The DNA methylation connection,” by L. Lu, R. C. Wylie, L.
G. Andrews, and T. Q. Tollefshol, 2003, Mechanisms of Ageing and Development, 124, 989-998.
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Figure 1.2. Mediators and moderators in cancer and chemotherapy induced cognitive decline

Figure 1.2. A schematic diagram of confounding variables involved in cancer and chemotherapy
induced neurotoxicity and cognitive decline. Adapted from “Candidate mechanisms for
chemotherapy-induced cognitive changes,” by T. A. Ahles and A. J. Saykin, 2007, Cancer, 7,
192-201.
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Figure 1.3. DNA methylation and transcription

Figure 1.3. A schematic diagram of how DNA methylation and unmethylation lead to activation
and silencing of subsequent genes. Adapted from “Epigenetics: an overview,” by R. Holiday,
1994, Developmental Genetics, 15, 453-457.
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Figure 1.4. Histone acetylation and transcription

Figure 1.4. A schematic diagram showing how histone acetylation leads to relaxation of
heterochromatin and promotes gene transcription. Adapted from “Manipulating the brain with
epigenetics,” by E. Korus, 2010, Nature Neuroscience, 13, 405-406.
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Figure 2.1. Experimental design for effects of doxorubicin on metabolic activity of PC12
neuronal cells

Figure 2.1. Laboratory procedure for experiment reported in Section 2.1.
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Figure 2.2. Experimental design for effects of in vitro digested red raspberry on metabolic activity
of PC12 neuronal cells

Figure 2.2. Laboratory procedure for experiment reported in Section 2.2.
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Figure 2.3. Experimental design for effects of in vitro digested red raspberry on metabolic
activity of doxorubicin treated PC12 neuronal cells

Figure 2.3. Laboratory procedure for experiment reported in Section 2.3.
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Figure 2.4. Experimental design for effects of in vitro digested red raspberry on neurite
growth of doxorubicin treated PC12 neuronal cells

Figure 2.4. Laboratory procedure for experiment reported in Section 2.4.
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Figure 2.5. Experimental design for effects of human plasma collected prior to and after
red raspberry consumption on metabolic activity of doxorubicin treated PC12 neuronal
cells

Figure 2.5. Laboratory procedure for experiment reported in Section 2.5.
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Figure 2.6. Experimental design for effects of doxorubicin, in vitro digested red raspberry,
and combination on DNA methylation of PC12 neuronal cells

Figure 2.6. Laboratory procedure for experiment reported in Section 2.6.
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Figure 3.1. Metabolic activity of doxorubicin treated PC12 neuronal cells

1.2
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Doxorubicin 0.01 μM
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Doxorubicin 0.1 μM
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Doxorubicin 10 μM

0.2

0.0

Figure 3.1. A bar chart comparison of metabolic activity changes of PC12 neuronal cells caused
by DOX treatments. The metabolic activities of PC12 neuronal cells treated with various
concentrations of DOX were all statistically different from the DMSO control. The results
indicated minute amounts of DOX reduced the metabolic activity of PC12 neuronal cells,
exibiting neurotoxicity. Data were compared by two-tail Student t-test with p < 0.05 considered
statistically significant.
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Figure 3.2. Metabolic activity of in vitro digested red raspberry treated PC12 neuronal cells
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Figure 3.2. A bar chart comparison of metabolic activity changes of PC12 neuronal cells caused by in
vitro digested RR treatments. Compared to control, metabolic activity of 0.0625% to 0.5% digested RR
treated PC12 neuronal cells increased and metabolic activity of 1% of in vitro digested RR treated cells
decreased without statistical significance. The results indicate 0.0625% to 0.5% in vitro digested RR
have the potential to promote metabolic activity of PC12 neuronal cells. Data were compared by two-tail
Student t-test with p < 0.05 considered statistically significant.
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Figure 3.3. Metabolic activity of in vitro digested red raspberry and doxorubicin treated PC12
neuronal cells
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Figure 3.3. A comparison of metabolic activity changes of PC12 neuronal cells caused by in vitro
digested RR and DOX treatments. The metabolic activity of PC12 neuronal cells treated with
combinations of in vitro digested RR and DOX were higher compared to that of cells treated with
DOX alone (p = 0.035 & 0.057 respectively). The results indicate in vitro digested RR
counteracted the neuro-toxic effect of low concentrations of DOX on metabolic activity of PC12
neuronal cells. Data were compared by two-tail Student t-test with p < 0.05 considered
statistically significant.
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Figure 3.4. Neurite growth of in vitro digested red raspberry and doxorubicin treated PC12
neuronal cells

A

B

C

D

E

F

Figure 3.4. A visual comparison of changes in neurite growth of PC12 neuronal cells caused by in vitro
digested RR and DOX treatments. DOX treated cells had less neurite connections compared to DOX plus
in vitro digested RR treated cells. The results indicate in vitro digested RR counteracted the neuro-toxic
effect of low concentrations of DOX on neurite connections of PC12 neuronal cells. Each picture
depicted the spot with the greatest number of neurites on the medium for each sample. The labels of the
pictures A-F correspond to A-F in Figure 3.3. A: Water treated cells; B: 0.1% digested RR treated cells;
C: 0.1µM DOX treated cells; D: 0.1% digested RR plus 0.1µM DOX treated cells; E: 1µM DOX treated
cells; F: 0.1% digested RR plus 1µM DOX treated cells.
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Figure 3.5. Cell metabolic activity ratio of 6 participants for pre-plasma and post-plasma
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Figure 3.5. A bar chart comparison of changes in metabolic activity of PC12 neuronal cells
treated with plasma of participants prior to and after consumption of RR. The calculated ratios
for post-plasma of participants #1-#4 were higher compared to ratios of their pre-plasma, while
the calculated ratios for post-plasma of participants #5-#6 were lower compared to ratios of their
pre-plasma. The average ratio of post-plasma for six participants was higher than that of preplasma. The results indicate metabolized RR may have the potential to counteract the neuro-toxic
effect of DOX with varied responses for different individuals.
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Figure 3.6. Methylation patterns of BDNF, EGR1 and FOS genes for highly methylated rat genomic
DNA

BDNF_U

BDNF_M
147bp

EGR1_U

EGR1_M
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Figure 3.6. Electrophoresis gel results depicting MSP products for highly methylated rat genomic
DNA, illustrating designed methylated-specific primers for BDNF, EGR1 and FOS genes work in
MSP. Unmethylated-specific primers; M: Methylated-specific primers.
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Figure 3.7. Methylation patterns of BDNF, EGR1 and FOS genes for DNA from PC12 neuronal
cells

FOS_U
192bp

BDNF_U
146bp

EGR1_U
131bp

Figure 3.7. Electrophoresis gel results depicting MSP products for DNA from PC12 neuronal
cells, illustrating designed unmethylated-specific primers for BDNF, EGR1 and FOS genes work
in MSP. U: Unmethylated-specific primers.
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Figure 3.8. Methylation pattern of FOS for DNA from PC12 neuronal cells and highly methylated
rat genomic DNA

Figure 3.8. Electrophoresis gel results depicting MSP products for DNA from highly methylated
rat and PC12 neuronal cells, illustrating designed methylated-specific primers and unmethylatedspecific primers for FOS gene work in MSP. U: Unmethylated-specific primers; M: Methylatedspecific primers.
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Figure 3.9. Repeated methylation pattern of FOS for DNA from the control and treated
PC12 neuronal cell samples

Figure 3.9. Electrophoresis gel results depicting MSP products for DNA from control and treated
PC12 neuronal cells harvested from different days. DOX and combination treated cells showed
methylation signals, while control and RR treated cells did not. The results indicate DOX
treatment may have induced FOS gene methylation in PC12 neuronal cells, while in vitro
digested RR did not reverse this effect. C: DNA of control PC12 neuronal cells; R: DNA of in
vitro digested RR treated PC12 neuronal cells; D: DNA of DOX treated PC12 neuronal cells; +:
DNA of PC12 neuronal cells treated with in vitro digested RR plus DOX; C1,R1,D1,+1: Cells
harvested on March 9th, 2011; C2,R2,D2,+2: Cells harvested on April 23rd, 2011; C3,R3,D3,+3:
Cells harvested on June 20th, 2011;
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Figure 3.10. Percentage of DNA samples that show electrophoresis bands for methylated FOS or
unmethylated FOS in MSP
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Figure 3.10. A bar chart of percentages of the control and treated PC12 neuronal cell samples that
showed bands in gel electrophoresis. This chart indicates a majority of sample sets share the
same DNA methylation pattern of FOS gene.

There were exceptions probably due to the

variability of maturation stages of PC12 samples from different days, the transient nature of
immediate early gene induction that is not easily captured, and the sensitive limit of MSP. M:
Methylated; U: Unmethylated; Control: DNA of control PC12 neuronal cells; DOX: DNA of
DOX treated PC12 neuronal cells; RR: DNA of in vitro digested RR treated PC12 neuronal cells;
DOX+RR: DNA of PC12 neuronal cells treated with DOX plus in vitro digested RR.
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Figure 4.1. Apoptosis induced by doxorubicin

Figure 4.1. A schematic diagram showing DOX induces apoptosis through P53 and Bax in brain
mitochondria. Adapted from “ Adriamycin-induced, TNF-α-mediated central nervous system
toxicity,” by J. Tangpong et al., 2006, Neurobiology of Diseases, 23, 127-139.
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Figure 4.2. Free radical mediated oxidation induced by doxorubicin

Figure 4.2. A schematic diagram showing DOX increases oxidative stress by generating superoxide radical O2- which participates in redox cycling. Adapted from “Prevention of doxorubicininduced acute cardiotoxicity by an experimental antioxidant compound,” by P. Deres et al., 2005,
Journal of Cardiovascular Pharmacology, 45, 36-43.
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Figure 4.3. Cytokine mediated nitration induced by doxorubicin

Figure 4.3. A schematic diagram showing DOX induces cytokines to generate oxidative stress.
Adapted from “Adriamycin-mediated nitration of manganese superoxide dismutase in the central
nervous system: insight into the mechanism of chemobrain, by J. Tangpong et al., 2007, Journal
of Neurochemistry, 100, 191-201.
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Figure 4.4. DNA damage induced by doxorubicin

Figure 4.4. A schematic diagram showing DOX interacts with DNA, helicase and topoisomerase
II to induce DNA damages. Adapted from “Structural Comparison of Anticancer Drug-DNA
complexes: Adriamycin and Daunomycin,” by C. A. Frederick et al., 1990, Biochemistry, 29,
2538-2549.
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Figure 4.5. Phenolic compounds work through multiple pathways

Figure 4.5. A schematic diagram illustrating phenolic compounds in RR work through multiple
pathways to exhibit neuro-protective effects. Adapted from “Grape juice, berries, and walnuts
affect brain aging and behavior,” by J. A. Joseph, B. Shukitt-Hale, and L. M. Willis, 2009, The
Journal of Nutrition, 139, 1813S-1817S.
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Figure 4.6. Comparision of in vitro digestion and in vivo metabolism

Figure 4.6. A schematic comparison of in vitro digestion and in vivo metabolism illustrating the
use of human plasma containing metabolized RR to treat neuronal cells better mimics what
happens in the human body. Adapted from “Bioavailability of various polyphenols from a diet
containing moderate amounts of berries, by R. Koli et al., 2010, Agricultural and Food
Chemistry, 58, 3927-3932.
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Figure A.1. A study design for future preliminary clinical research

Figure A.1. A schematic illustration of a study design for future preliminary clinical research.
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